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 6 
Introduction 
 
The last two decades have witnessed rapid developments in –omics 
technologies which enable the study of biological and disease processes in a high 
throughput manner. Among the -omics approaches, genomics and the related 
bioinformatic methods have emerged as most popular applications able to accelerate 
science discoveries in basic research and drug discovery and therapeutics.  
Genomics is an interdisciplinary field of science focusing on the structure, function, 
evolution, mapping, and editing of genomes (Wikipedia, url: 
https://en.wikipedia.org/wiki/Genomics). Over the years, the field of genomics has 
undergone several revolutions. Prior to the advent of Next Generation Sequencing 
(NGS), genomics was limited to the characterization of single disease-associated genes 
(e.g. Huntington disease, cystic fibrosis, cancer) or to the study of small genomes (e.g. 
bacteria, viruses). As physical mapping with large-insert clones became possible, the 
subcloned fragments of large genomes could be sequenced as individual projects, and 
their finished sequences combined together to reconstruct the sequence of entire 
chromosomes. Using this approach and beginning from 1985, in 2003 the Human 
Genome Project was able to complete the sequence of the DNA in the human genome 
(I. H. G. S. Consortium et al., 2001; Venter et al., 2001), thus providing a basic 
platform for the development of new technologies. In the same period, other large 
genomes, including those of model organisms, were also decoded (M. G. S. 
Consortium et al., 2002; R. G. S. P. Consortium et al., 2004; Myers et al., 2000). 
Hybridization-based methods such as microarrays exploited the information gained 
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from genome projects to develop rapid, high throughput assays to allow the 
measurement of genetic variation, gene expression and chromatin binding, which 
spread rapidly in all fields of research. Most recently, these methods were quickly 
replaced by NGS, which allows similar studies to be conducted with much higher 
sensitivity and in an unbiased whole-genome and –transcriptome fashion. As a result, 
sequencing has become an essential and obligatory tool and not only for biologists.  
In the early days of NGS, the initial focus of every genomic scientist was on the de-
novo assembly of novel genomes for species that were never sequenced before. These 
efforts led to the completion of many novel genomic sequences which include even 
large genomes of mammals and plants. In the case of de-novo assembly, the genomic 
sequence is built from scratch without the use of an existing scaffold. Advances in 
sequencing technology have recently led to a dramatic increase in speed and 
throughput capacity, and a sharp reduction in costs. These improvements enabled the 
shift from de-novo to re-sequencing of entire genomes from additional individuals of 
species already sequenced. In the case of re-sequencing, short reads can be aligned to 
reference genomes as a substrate for variation discovery or gene expression analysis. 
Re-sequencing applications provide the scientific community with an unprecedented 
opportunity to address fundamental evolutionary questions, as well as to extend the 
use of sequencing to population genetic studies to infer ancient population history. The 
availability of new data types given by an always increasing number of NGS 
applications continues to engage and excite the computational biology community 
working on software development and on the analysis of new data types generated to 
solve complex biomedical problems.  
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In this context, the main objective of my research was to explore different biological 
systems to identify new molecular signals through the development and 
implementation of genomic and bioinformatic methods. This objective was 
accomplished by participating to three different research projects where I applied 
genomic and bioinformatic solutions to different areas of biology: genome 
composition, organization and regulation, malaria biology, and cancer. The first 
chapter provides an introduction to the main technology and biology concepts explored 
in my research, while the following three chapters describe in details the research work 
conducted during my studies.  
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Chapter I 
 
Next Generation Sequencing applications for research: a 
genomics (r)evolution. 
 
The use of sequencers as molecule-counting devices is immensely popular. 
DNA sequencers are capable of sequencing large numbers of different DNA fragments 
in parallel in a single reaction. In general, NGS experiments consist of 4 phases: 
sample collection, template generation, sequencing reactions and detection, and data 
analysis. All the sequencing methods monitor the sequential addition of nucleotides to 
immobilized and spatially arrayed DNA templates in more or less similar ways, but 
mostly differ in how the templates are generated and interrogated to obtain the 
sequences (Linnarsson, 2010). Figure 1 shows a basic workflow for NGS analysis 
(Rizzo & Buck, 2012).  
The range and the scope of DNA sequencing applications is very broad and largely 
depends on the biological questions to address in the study (Figure 1). Normal and 
diseased tissues can be used as source for the extraction of nucleic acids in a whole 
genome or targeted experiment. Among the most popular applications, whole genome 
sequencing starts from genomic DNA as input and can be applied to human genetics 
and evolution studies for the detection of genome-wide genetic variations like Single 
Nucleotide Polymorphims (SNPs), Insertion and Deletions (InDels), large genomic 
rearrangements (e.g. large deletions, duplications, insertions, inversions or 
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translocations), and even DNA repeats like Short Tandem Repeats (STRs). Whole 
genome sequencing can also provide information on cancer and disease-associated 
mutations, which makes it a key application in the field of precision medicine. 
Alternatively to the whole genome, whole-exome sequencing can be used for 
sequencing all of the known exons of protein-coding genes in a genome (known as the 
“exome”). This method also starts from genomic DNA and consists of a first step to 
select only the subset of DNA that encodes proteins (the “exons”) and a second step 
to sequence the selected exonic DNA using any high-throughput sequencing 
technology.   
Transcriptome sequencing starts from either total RNA or enriched RNA fractions. 
This application is based on shotgun sequencing of either full-length or 3′ ends of 
cDNA, and is used to reveal the presence, quantity and structure of RNA in a biological 
sample under specific conditions (Wang, Gerstein, & Snyder, 2009). Compared to 
hybridization-based RNA quantification methods such as microarrays, sequencing-
based transcriptome detection can quantify gene expression with low background, high 
accuracy and high levels of reproducibility within a large dynamic range. In addition, 
transcriptome sequencing does not require an existing genome sequence and can detect 
mutations, splice variants and fusion genes that cannot be detected by microarrays. 
Among the library preparation methods available, the standard poly(A)+ enrichment 
provides a comprehensive, detailed, and accurate view of polyadenylated RNAs. 
However, on samples of suboptimal quality ribosomal RNA depletion and exon 
capture methods have recently been reported as better alternatives (S. Schuierer et al., 
2017).  
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ChIP-sequencing is widely used to analyze protein-DNA interactions for epigenetic 
studies. It combines chromatin immunoprecipitation (ChIP) with massively parallel 
DNA sequencing to identify binding sites of DNA-associated proteins, and can be used 
to precisely map global binding sites for any protein of interest. ChIP sequencing offers 
higher resolution and more precise and abundant information in comparison with 
array-based ChIP-on-chip. Likewise ChIP-seq for the genomic DNA, RIP-Sequencing 
identifies the binding sites of proteins to the RNA within RNA-protein complexes 
extracted through immunoprecipitation with antibodies targeting the protein of 
interest. After RNase digestion, the RNA fragments protected by protein binding are 
extracted, reverse-transcribed to cDNA and sequenced.  
The above-listed NGS applications, and in general all the methods shown in Figure 1, 
generate nucleic acids (e.g. genomic DNA, immunoprecipitated DNA, total RNA, 
enriched RNA fractions) that in the case of RNA need to be converted into double-
stranded DNA (dsDNA) to proceed with the library preparation. These dsDNA 
fragments are subsequently converted into a “library” of sequencing templates, 
through standard steps of fragmentation, size selection, and adapter ligation. 
Fragmentation allows to break the DNA templates into smaller “sequenceable” 
fragments, which are then “size-selected” to enrich for fragments of a size range that 
is compatible with the sequencing platform’s specifications. The ligation of platform-
specific primers (or adapters) to the ends of the library fragments is used to enable 
priming for downstream amplification (e.g. clustering generation) and the sequencing 
reactions. Depending on the NGS technology used, a library is either sequenced 
directly or is amplified then sequenced (e.g. cluster generation via bridge 
amplification). Template generation also serves to spatially separate and immobilize 
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DNA fragment populations for sequencing, typically by attachment to solid surfaces 
(e.g. a flow cell) or beads. This allows the downstream sequencing reaction to operate 
as millions of microreactions carried out in parallel on each spatially distinct template.   
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Figure 1. Basic workflow for NGS experiments. 
 
Source: Rizzo and Buck, Cancer Prevention Research, 2012. 
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Bioinformatics: turning data into knowledge. 
Driven by the rapid introduction of high-throughput sequencing in biological 
research, data generation has shifted to become faster and cheaper while data have 
been growing in complexity, diversity, and volume. This poses an important challenge 
to those research institutes that are not adequately prepared for the storage and for the 
high-performance computing analysis of “big data” and are required to access the 
external cloud computing to scale up to extra informatics capacity. Moreover, 
investing in the training of the next generation of scientists on “data science” 
disciplines is becoming fundamental for all research centers nowadays. 
Bioinformatics is an interdisciplinary field that develops methods, databases, and 
software for the management, analysis and interpretation of biological data. As 
important as techniques to produce the NGS data are, bioinformatic approaches are 
equally critical for the successful analysis of those data. Many analytical approaches 
depend on the digital nature of NGS data, which depends on how the individual DNA 
fragments of the library are prepared prior to the sequencing reaction (e.g. targeted or 
whole genome). These fragments can be sequenced either as single-read or paired-end 
reads (e.g. originating from both ends of the molecule) to generate the raw data used 
for downstream analysis (Figure 1). The description of the standard RNA-seq 
workflow can serve as an example of how bioinformatics is applied to NGS data 
analysis. 
The main goal of a standard RNA-seq experiment is to identify differentially expressed 
genes between two or more groups of biological samples. To this purpose, an end-to-
end gene-level RNA-Seq differential expression workflow include four major steps 
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such as quality control, alignment, quantification and identification of differentially 
expressed genes (Figure 2). First, raw NGS reads undergo quality assessment and 
filtering. Second, the quality-filtered reads in Fastq format are aligned against 
reference sequences (e.g. genome or transcriptome). The choice of the right reference 
genome and annotation is key for the success of the downstream analysis. Third, 
expression estimates are derived from the aligned reads to obtain the gene expression 
counts. For baseline expression, gene counts, which represent the total number of reads 
aligned to each gene, can be further transformed into Counts Per Million (CPM; 
normalization by total number of mapped reads per sample) or Fragments per Kilobase 
of exon per Million of fragments mapped (FPKM; further normalization by effective 
gene length). Fourth, for differential analysis, these count estimates are used to identify 
differentially expressed genes, usually by computing fold changes and P-values 
(Figure 2). The bioinformatic community has been very proficient in the development 
of software tools for the analysis of RNA-seq gene expression data. Tophat2 (Kim et 
al., 2013) and STAR (Dobin et al., 2013) are among the most popular aligners; EQP 
(Sven Schuierer & Roma, 2016), htseq-count (Anders, Pyl, & Huber, 2015), 
featureCounts (Liao, Smyth, & Shi, 2014) and Cufflinks2 (Trapnell et al., 2012) are 
used for the quantification step for the generation of gene counts. DESeq2 (Love, 
Huber, & Anders, 2014) and Cuffdiff (Trapnell et al., 2012) are used for the differential 
gene expression analysis.  
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Figure 2. The major steps of a standard RNA-seq workflow.  
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Use of public resources for integrative data analysis. 
 
  
Over the last decades, the scientific community has generated an immense 
amount of genomic data that is now deposited in large public repositories and available 
to other scientists wanting to conduct further analyses. For instance, reference genome 
sequences and annotation files can be accessed in genomic repositories like the 
“Ensembl Genome database” developed by the European Bioinformatics Institute 
(EBI) and the Wellcome Trust Sanger Institute in UK  (Zerbino et al., 2018), the 
“UCSC Genome Browser” hosted at the University of Santa Cruz in California (Casper 
et al., 2018), and the “Genome Portal” of the Joint Genome Institute (JGI) (Nordberg 
et al., 2014), or even in species-specific repositories as for instance “PlasmoDB” which 
is a genome database for the genus Plasmodia useful to study the biology of the malaria 
parasites (Aurrecoechea et al., 2009).  
Likewise, there has been a multitude of NGS experimental datasets deposited in the 
public domain which provides unprecedented opportunities for computational 
scientists to explore biology by data integrative approaches. For instance, the NCBI 
Sequence Read Archive (SRA, https://www.ncbi.nlm.nih.gov/sra) (Leinonen, 
Sugawara, & Shumway, 2011) and the European Nucleotide Archive (ENA, 
https://www.ebi.ac.uk/ena) (Leinonen, Akhtar, et al., 2011) are major public 
repositories hosting sequencing data generated by individual scientists or large 
consortia. In addition, for human relevant datasets, the database of Genotypes and 
Phenotypes (dbGAP, https://www.ncbi.nlm.nih.gov/gap) hosts and distributes the data 
and results from studies that have investigated the interaction of genotype and 
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phenotype in humans (Tryka et al., 2014); similarly, the recent European Genome-
phenome Archive (EGA, https://ega-archive.org) enables the archiving and sharing of 
all types of personally identifiable genetic and phenotypic data resulting from 
biomedical research projects (Lappalainen et al., 2015). Large scale sequencing 
projects that are led by public or private consortia routinely share their datasets in one 
or more of these repositories. Examples related to cancer studies are provided by The 
Cancer Genome Atlas Research Network Atlas (TCGA, 
https://cancergenome.nih.gov) (Gao et al., 2013; Hutter & Zenklusen, 2018), the 
Cancer Cell Line Encyclopedia (CCLE, https://portals.broadinstitute.org/ccle) 
(Barretina et al., 2012), and the Catalogue Of Somatic Mutations In Cancer (COSMIC, 
https://cancer.sanger.ac.uk/cosmic) (Forbes et al., 2017). The sequencing results 
generated by these large cancer projects, for instance, could be compared with the 
sequencing information from 53 non-diseased tissue sites across nearly 1000 
individuals obtained by the Genotype-Tissue Expression (GTEx) project (The GTEx 
Consortium, 2013).  
Data sharing is more and more considered good practice in computational biology to 
ensure research reproducibility. To enhance data reusability, the scientific community 
has been working on making the data FAIR, e.g. Findable, Accessible, Interoperable, 
and Reusable according to the FAIR principles (Wilkinson et al., 2016). For the same 
reason, scientific journals often require deposition of raw sequencing data and 
downstream results in public repository. This means that other scientists may access 
these data and materials in the future to conduct further research on these subjects. 
Integrative data analysis is an emerging field of study that investigates strategies, 
algorithms and implementations of combining data from different sources and applies 
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systems biology approaches in solving complex biomedical problems. Genomics, 
transcriptomics, proteomics and metabolomics are being combined in a systems 
biology approach to understand the biological system as a whole rather than focusing 
on individual factors. Being at the core of this new discipline, genomics approaches 
are now converging rapidly through the use of next-generation sequencing which 
enables, via a single technology, the acquisition of large datasets on genetic markers, 
epigenetic markers, transcriptome profiles, translational profiling, as well as 
relationships amongst these. The integration of such genomic datasets with proteomic 
and metabolomic data require the development of novel approaches for meta-analysis. 
Multi-omics studies are highly promising but also challenging as profound coordinated 
efforts in bioinformatics and biostatistics are required to connect the individual factors. 
One major challenge is represented by the heterogeneity of data formats that are 
generated by the different omic- technologies. Integration of more than two different 
omics data formats is still not routine and requires optimized software tools together 
with well-trained computational scientists to generate comprehensible workflows for 
the analysis of big data.  
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Diatoms: a biological model for regulatory genomics. 
 
Marine diatoms are unicellular photosynthetic algae and a key phytoplankton 
group in the ocean (Armbrust, 2009). They play a fundamental role in global carbon 
cycles as they are estimated to be responsible for about 20% of global primary 
productivity (Armbrust, 2009; Smith et al., 2015). Diatoms have played a decisive role 
in the ecosystem for millions of years for the enormous amount of oxygen they 
generate on earth and for being the most important sources of biomass in oceans. These 
single-celled organisms are being studied in several commercial and industrial 
applications for the production of carbon-neutral fuels, pharmaceuticals, foods, 
biomolecules, nanomaterials, and for the bioremediation of contaminated water 
(Bozarth, Maier, & Zauner, 2009). Diatom cells are surrounded by a silica wall known 
as a “frustule” made up of two valves called “thecae”, that typically overlap one 
another. Based on the shape of their frustule diatoms are classified into: 1) Centrales, 
centric diatoms that are radially symmetrical; 2) Pennales, pennate diatoms that are 
bilaterally symmetrical (Armbrust, 2009). The frustules of death diatoms sink to the 
bottom of the oceans and decomposes into diatomite, a remnant material that is used 
commercially as filters, mineral fillers, insulation material, insecticide, anti-caking 
agents, or fine abrasive. These simple eukaryotic organisms are of interest to many 
biologists for their extraordinary capacity to rapidly adapt to new environments. They 
represent an unique evolutionary model for investigating the role of genomic 
sequences in evolution (Russo, Annunziata, Sanges, Ferrante, & Falciatore, 2015).  
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The study described in Chapter II exemplifies the application of genomics and 
bioinformatics to the study of short tandem repeats (STRs) in diatoms. Specifically, it 
provides an alternative to the classical view of evolution in which changes occur via 
the accumulation of single point mutations by extending it to the inclusion of 
additional mechanisms that allow for the rapid gain, loss, and rearrangement of 
significant portions of the genome for instance through dynamic expansion or  
contraction of short repetitive sequences. These dynamic modifications of the genomes 
are truly fascinating as they enable simple organisms like protists to evolve rapidly in 
response to environmental changes, accounting for their wide dissemination in the 
biosphere. The study identified and characterized STR sequences in all the diatom 
genomes sequenced so far, including the Pennate diatoms Phaeodactylum tricornutum 
(Bowler et al., 2008), Pseudo-nitzschia multistriata (Basu et al., 2017) and 
Fragilariopsis cylindrus (Mock et al., 2017), and the centric diatom Thalassiosira 
pseudonana (Armbrust et al., 2004) (Figure 3). Results show, for the first time, that 
these genomes are enriched in triplet repeats that are mostly located in gene regulatory 
regions like promoters. 
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Figure 3. Marine diatoms sequenced to date. 
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Understanding the biology of the sleeping malaria parasite. 
 
Malaria is a life-threatening disease transmitted to humans through the bite of 
an infected Anopheles mosquito carrying the Plasmodium parasite. More than 100 
species of Plasmodium have been identified so far, of which only four have long been 
recognized to infect humans: P. falciparum, P. vivax, P. ovale and P. malariae.  
At the beginning of the parasite life cycle, female mosquitoes take blood meals to carry 
out egg production (Figure 4). Once injected in the human skin, the sporozoites rapidly 
leave the injection site and migrate through the bloodstream to the liver, where they 
invade hepatocytes and develop into the growing liver stage, the “schizonts”. P. vivax 
and P. Ovale, however, can form dormant liver stages called “hypnozoites” that can 
re-activate months or years later giving rise to clinical malaria (relapses) without being 
exposed to new infectious mosquito bites. The schizonts parasites grow and multiply 
first in the liver cells and then in the red blood cells. When growing inside these cells 
the parasites destroy them, releasing daughter parasites called “merozoites” that 
continue the cycle by invading other cells. Malaria symptoms (like fever, headache, 
nausea, vomiting, abdominal pain, diarrhea, among others) are caused by the blood 
stage parasites. In the blood stream the parasites enter the asexual cycle. There the new 
forms termed “gametocytes” can be picked up by a female Anopheles mosquito during 
a new blood meal to start another cycle of growth and multiplication in the mosquito. 
Thus the mosquito acts as a vector carrying the disease from one human to another. 
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P. vivax is the major cause of malaria outside of Africa with an estimated 13.8 
million malaria cases globally in 2015 (World Health Organization (WHO), 2015). 
Eradication of vivax malaria will only be feasible if effective and well-tolerated 
therapies kill hypnozoites and hence prevent disease relapse. Recently, the FDA 
approved tafenoquine as a radical cure therapy and prophylactic for P. vivax malaria 
infection (Frampton, 2018). This represents a significant advance in the field as 
tafenoquine is administered as a single dose regimen, which is a very important 
improvement for patient compliance when compared to the 14-day long drug regimen 
of its closely related predecessor primaquine. Like primaquine, tafenoquine cannot be 
administered to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, 
a common genetic disorder in malaria endemic countries, due to serious adverse side-
effects and life-threatening drug-induced hemolysis (Mazier, Rénia, & Snounou, 2009; 
Wells, Burrows, & Baird, 2010). For this reason, new drugs are urgently needed to 
achieve malaria elimination.  
The second study presented in Chapter III describes the application of genomics and 
bioinformatics for the transcriptomic analysis of the malaria hypnozoites. Using a 
combination of genetically engineered fluorescent P. cynomolgi parasites (the P. vivax 
sister parasites displaying identical biology in the monkeys), in vitro liver stage 
culture, cell-sorting and RNA-seq, primary monkey hepatocytes were profiled six and 
seven days after infection with the Plasmodium parasites to investigate the hypnozoite 
biology. The analysis of the sequencing data revealed that hypnozoites have a reduced 
transcriptional rate and express a lower number of genes compared to schizonts, the 
hepatic forms of the developing parasite. While the schizonts express 91% of the 
Plasmodium cell pathways, the hypnozoites globally repress the gene expression to a 
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minimum number of biological pathways that allow only the maintenance of the basic 
cellular functions necessary for its survival in the host hepatocyte. This data set and 
the analyses carried out represent a precious resource for the discovery of new vaccines 
and effective treatments to combat malaria. 
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Figure 4. Malaria parasite life cycle. 
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Hepatocellular carcinoma: the third leading cause of cancer 
deaths worldwide. 
 
Representing more than 90% of all primary liver malignancies, hepatocellular 
carcinoma (HCC) is one of the few cancer types with rising incidence and mortality. 
This cancer occurs primarily in patients affected by chronic liver disease and cirrhosis. 
Although still under investigation, it is hypothesized that hepatic stem cells are the 
cells that give rise to this disease. Available treatments include only three approved 
systemic agents, namely sorafenib and regorafenib (both kinase inhibitors) and 
nivolumab (immune checkpoint inhibitor). Despite the extensive genomic and 
transcriptomic characterization of the features and diversity of HCC, there is still a 
urgent need for the identification of novel therapeutic targets in HCC and of robust 
biomarkers of response to therapy. 
Cancer is a genetic disease caused by accumulation of DNA mutations and epigenetic 
alterations leading to uncontrolled cell proliferation and tumor formation. Genes 
involved in liver metabolism, Wnt and p53 signalling have been shown to be 
recurrently altered in HCC (Ahn et al., 2014; Ally et al., 2017; Fujimoto et al., 2012; 
Guichard et al., 2012; Hutter & Zenklusen, 2018; Schulze et al., 2015). CTNNB1 (β-
catenin) and TP53 (p53) are the most frequently mutated protein-coding genes, both 
mutated in 20–40% of HCC patients (Ahn et al., 2014; Ally et al., 2017; Fujimoto et 
al., 2012; Guichard et al., 2012; Hutter & Zenklusen, 2018; Schulze et al., 2015). TP53 
is also the most frequently mutated gene in human cancer (Kandoth et al., 2013) 
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(Figure 5). The p53 protein modulates multiple cellular functions, including 
transcription, DNA synthesis and repair, cell cycle arrest, senescence and apoptosis 
(Vogelstein, Lane, & Levine, 2000). Mutations in TP53 can abrogate these functions, 
leading to genetic instability and progression to cancer (Vogelstein et al., 2000). 
The third study, presented in Chapter IV, exemplifies the use of genomics and 
bioinformatics to discover new molecular signals in the patients affected by 
hepatocellular carcinoma and bearing mutations in the TP53 gene. Taking advantage 
of the public RNA-seq data sets from The Cancer Genome Atlas (TCGA), the study 
defines the spectrum of the TP53 somatic mutations in HCC patients and its 
association with clinicopathologic features. Four distinct subsets of TP53 mutations, 
each characterized by specific molecular signals, were identified from 373 HCC cases. 
Patients with TP53 mutations had worse survival than patients with wild-type TP53. 
The study indicated that some genetic heterogeneity of the TP53 mutation exists in 
HCC cancer and that mutations in TP53 should be considered for the molecular 
characterization of HCC.  
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Figure 5. The 127 Significantly Mutated Genes (SMGs) from 20 cellular processes in cancer 
identified in 12 cancer types. 
 
Source: Kandoth et al, Nature, 2013. 
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Chapter II 
 
Short tandem repeats are enriched in promoters of diatom 
genes 
 
 
Abstract  
 
To date, short tandem repeats (STRs) remain understudied in lower eukaryotes. Here, 
we present the first genome-wide survey of STRs in four marine diatom genomes, 
including the pennate diatoms Phaeodactylum tricornutum, Pseudo-nitzschia 
multistriata and Fragilariopsis cylindrus and the centric diatom Thalassiosira 
pseudonana. For the first time we discover that the most common STRs in diatom 
genomes are triplets, of which AAC is the most abundant. We found that over 75% of 
STRs are located in non-coding regions, particularly in promoters and in intronic 
regions. AAC is the most frequent repeat in the promoters of all diatom species, while 
AGT and ACT are copious only in P. multistriata promoters and TATA-box like DNA 
motifs (like AAT and ATT) only in F. cylindrus promoters. The presence of these 
repeats in diatom promoters might lead, in the cases of their expansion, to the gain of 
regulatory motifs upstream of the TSS or to their loss in cases of reduction. These 
sequences have therefore the capability to modulate gene expression. This dataset is a 
valuable resource to investigate transcriptional regulation in lower eukaryotes. 
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Introduction 
 
Tandem repeats are an abundant class of genomic sequences that mutate faster 
than the surrounding genome (Lynch et al., 2008; Richard, Kerrest, & Dujon, 2008). 
At each cell division, these unstable genomic elements may change in the number of 
repeat units during DNA replication. These sequences, formerly-thought of as junk 
DNA, became of age as they are used as genomic markers and DNA fingerprints, are 
involved in human disease, and are linked to the evolution of coding and regulatory 
regions (Gemayel, Vinces, Legendre, & Verstrepen, 2010). Tandem repeats are 
composed of a short DNA motif, the so-called repeat unit, that is repeated several times 
head-to-tail. Based on the size of the repeat unit (or period size), tandem repeats are 
classified into microsatellites (unit size <10nt; also known as short tandem repeats, 
STRs) or minisatellites (unit size ³10nt). Microsatellites are the most prevalent types 
of repeats (Ellegren, 2004; Gemayel et al., 2010).  
Recent studies have shown that STRs are ubiquitous and abundant in higher eukaryotic 
genomes (Gemayel et al., 2010). They occupy 3% of the human genome and are 
mainly located in coding regions and in gene expression regulatory regions like 
promoters (Sawaya et al., 2013). STRs located in such functional regions can modulate 
phenotypes via expansion or contraction of their repeat units thus potentially leading 
to an evolutionary advantage (Iii, Hammock, Hannan, & King, 2008) or even the onset 
of human diseases (Campuzano et al., n.d.; Day JW, n.d.; Gijselinck et al., 2012; 
Maclean, Warne, & Zajac, 1996; Orr & Zoghbi, 2007; Richard et al., 2008; Sawaya et 
al., 2013; Tabolacci, Palumbo, Nobile, & Neri, 2016).  
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STRs have also been observed in promoters of other eukaryotic genomes including 
single-celled organisms like yeast (Vinces, Legendre, Caldara, Hagihara, & 
Verstrepen, 2011) and complex organisms like birds (Abe & Gemmell, 2016), dogs 
(Eo et al., 2016), monkeys (Ohadi M, Valipour E, Ghadimi-Haddadan S, Namdar-
Aligoodarzi P & Kowsari A, Rezazadeh M, Darvish H, 2014) or humans (Sawaya et 
al., 2013). Vinces et al. found that STRs can affect gene expression by acting as 
nucleosome inhibitory sequences that maintain an open chromatin structure in specific 
regions of the promoter (Vinces et al., 2011). These authors propose a possible role of 
tandem repeats as nucleosome positioning elements in eukaryotes (Vinces et al., 2011). 
Similarly, Sawaya et al. described that STRs are abundant in human promoters, often 
highly conserved, and enriched near the transcriptional start sites (TSS) of key 
regulatory genes involved in growth and development. These authors suggest that 
promoter STRs have the potential to affect promoter function by generating mutations 
in regulatory elements, which may ultimately lead to variation in phenotypes (Sawaya 
et al., 2013). Finally, Sonay et al. showed that tandem repeats have taken an 
evolutionary role in gene expression differences in human and ape grape populations 
since genes with tandem repeats had higher expression divergence than genes without 
repeats, in the following order of decreasing divergence: repeats in 3’UTR, exons, 
promoters, 1st intron, and other introns (Sonay et al., 2015). While these findings 
highlight the potential contribution of STRs to evolution, they mostly refer to studies 
in higher eukaryotes. However, it remains still unknown whether STRs are also present 
and possibly control gene expression in simpler eukaryotic organisms like protists.  
Diatoms are unicellular photosynthetic algae and a key phytoplankton group in the 
contemporary ocean (Vardi, Thamatrakoln, Bidle, & Falkowski, 2009). These species 
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played a decisive role in the ecosystem for millions of years as one of the foremost set 
of oxygen synthesizers on earth and as one of the most important sources of biomass 
in oceans (Armbrust, 2009). Diatoms are used in commercial and industrial 
applications as the carbon neutral synthesis of fuels, pharmaceuticals, health foods, 
biomolecules, materials relevant to nanotechnology, and bioremediators of 
contaminated water (Bozarth, Maier, & Zauner, 2009). These single-celled organisms 
show extraordinary adaptation capacities to rapidly changing environments and 
therefore represent an important evolutionary model for investigating the role of 
tandem repeats in evolution (Russo, Annunziata, Sanges, Ferrante, & Falciatore, 
2015). Here we provide the first genome-wide survey of STRs in diatoms. Using an 
in-house bioinformatic workflow, we identified STRs in the four diatom genomes 
sequenced to date.  
 
Methods 
 
Identification of short tandem repeats in diatom genomes 
 
For the identification of STRs in whole genomes, we gathered genome FASTA 
files and annotation GTF files of the four diatoms listed in Table 1. The P. tricornutum 
and T. pseudonana reference files were retrieved from the Protists Ensembl database 
(http://protists.ensembl.org/) (Kersey et al., 2016); the F. cylindrus genome was 
obtained from the Joint Genome Institute (JGI) Genome Portal 
(http://genome.jgi.doe.gov) (Nordberg et al., 2014); finally, the P. multistriata 
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reference genome was recently sequenced at our institute (Basu et al., 2017). Diatom 
genomes were interrogated for the presence of STRs using the Phobos software version 
3.3.12 (Mayer, 2007) with default options except for minUnitLen=2 to exclude 
homopolymer repeats and outputFormat=3 to generate the one-per-line tabular 
format. The software selected STRs with a minimum length of 8 bp and a unit size of 
at least 2 (e.g. from 4 dinucleotides, 3 trinucleotides and 2 tetranucleotides). We wrote 
a Perl script to parse this output and to summarize STR features such as the 
chromosomal location, repeat size, copy number, alignment score, consensus and 
sequence. As a quality control, we visually inspected examples of tandem repeats from 
P. tricornutum and T. pseudonana using the Ensembl genome browser (Kersey et al., 
2016). In addition, the presence of specific STRs (e.g. CCTAAC repeats known to be 
located at the telomere regions) was confirmed using Ensembl karyotype plots to 
assess the correctness of our analysis. GTF files from the four diatoms were used as 
the source to annotate the repeats. For each STR, we used intersectBed from the 
BEDTools suite (Quinlan & Hall, 2010) to verify if it overlapped a promoter region 
defined as 500 bp upstream of the transcriptional start site (promoter-TSS), a gene 
exon (exon), a gene intron (intron), or none of the above features (intergenic). The 
STR occurrences were then normalized by the size of the feature as annotated in the 
reference genomes. Finally, we used genomecov from the BEDTools suite to compute 
the coverage of the repeat features in the region surrounding the gene TSS. The 
distribution plots presented in this article were generated with scripts written in the R 
language (R Core Team, 2013).  
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Identification of short tandem repeats in diatom promoters 
 
An in-depth analysis was carried out in promoter regions of each diatom 
genome. Here, we defined promoters as the sequences of the 500 bp upstream of each 
gene TSS, collected in the same orientation with respect to the coding strand of the 
related gene. Each promoter sequence was then randomized to obtain 1,000 random, 
shuffled sequences. In each randomization, the sequence of the promoter was shuffled 
so that we maintained the same base composition and length but created a non-
biologically meaningful sequence. Promoter and shuffled sequences were inspected 
for the presence of STRs by running Phobos version 3.3.12 (Mayer, 2007) using the 
options reportUnit=1 to conduct a strand-specific analysis, minUnitLen=2 to exclude 
homopolymer repeats, and outputFormat=3 to generate the one-per-line output format 
that is easier to parse. As in the genome-wide analysis, the software selected STRs 
with a minimum length of 8 bp and a unit size of at least 2 (e.g. from 4 dinucleotides, 
3 trinucleotides and 2 tetranucleotides). To assess the statistical enrichment of STRs 
in promoters, the occurrences of each STR were counted in both the real and the 
randomized data sets, and the corresponding statistics were calculated. Calculations 
based on the shuffled promoters represent the 'expected' frequencies of the STRs based 
solely on the nucleotidic composition and were used to calculate the Z-scores, while 
the calculations based on real promoters represent the 'observed' occurrences. 
Functional enrichment analysis was conducted performing the Fisher exact test 
comparing for each class the proportion of class specific genes in the total set of 
annotated genes with the proportion of class specific genes in the set associated to the 
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specific promoters. P-values were corrected using the Benjamini and Hochberg (BH) 
method. 
A similar strand-specific STR analysis was performed for the genomic regions 
surrounding the gene TSS to generate the metagene plots shown in Figure 4. 
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Results 
 
Diatom genomes are enriched in triplet repeats 
 
To generate a comprehensive catalogue of STRs in marine diatoms, we 
surveyed the genomes of four different species: i) the centric diatom Thalassiosira 
pseudonana, ii) the pennate diatom Phaeodactylum tricornutum, iii) the psychrophilic 
diatom Fragilariopsis cylindrus, and iv) the neurotoxin domoic acid-producing 
pennate diatom Pseudo-nitzschia multistriata. We found that the total number of STRs 
varies enormously among the species, ranging from a minimum of 51,042 sequences 
in P. tricornutum to a maximum of 472,979 in F. cylindrus (Table 1). Not surprisingly, 
we found that the total number of STRs increases with the genome size (Table 1). 
Over 86% of the STRs are perfect, pure repeats. In order to verify the correctness of 
our predictions, we searched for and confirmed the presence of CCTAAC repeats that 
are normally located at the telomere regions of each chromosome. From the STR 
analysis we gathered the full list of diatom repeats along with their chromosomal 
location, repeat size, copy number, alignment score, consensus and sequence.  
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 Phaeodactylum 
Tricornutum 
Thalassiosira 
Pseudonana 
Pseudo-
nitzschia 
multistriata 
Fragilariopsis 
cylindrus 
Genome ASM15095v2, Feb 2010 
ASM14940v2, May 
2014 Psmu1.4, Jul 2015 
CCMP1102 v1, 
Nov 2008 
  Length 27,568,093 32,437,365 59,304,822 80,540,407 
  Scaffolds 89 64 1,099 271 
  GC % 47.46 45.59 45.48 38.92 
  Genes 12,392 11,870 12,008 37,171 
  Source Ensembl Ensembl Internal JGI 
     
STRs perfect imperfect perfect imperfect perfect imperfect perfect imperfect 
  Di-nucleotide 5,101 270 7,210 430 8,526  649 26,629 4,047 
  Tri- 14,263 824 40,617 3,198 65,289 9,390 169,655 27,268 
  Tetra- 7,769 423 10,380 634 22,745 2,416 49,622 5,416 
  Penta- 7,203 262 11,482 624 26,711 3,998 50,793 7,420 
  Hexa- 11,564 466 21,260 955 40,328 6,422 85,833 14,930 
  Hepta- 1,635 65 3,838 202 10,030  904 13,734 1,551 
  Octa- 573 40 796 135 2,546  385 5,055  732 
  Nona- 394 40 795 80 2,958  845 6,842 1,840 
  Deca- 100 50 120 22  896  353 1,141  471 
  Total  
   (%) 
4,602  
(95.2) 
2,440  
(4.8) 
96,498 
(93.9) 
6,280  
(6.1) 
180,029 
(87.7) 
25,362 
(12.3) 
409,304 
(86.6) 
63,675 
(13.4) 
     
Total STRs 51,042 102,778 205,391 472,979 
Total STRs 
per genome 
length (kb) 
 
1.85 
 
3.17 
 
3.46 
 
5.87 
 
Table 1. Summary of short tandem repeats detected in diatom genomes. 
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Typically, STRs can vary in the size and in the number of copies of their repeat units. 
For the first time, we report that the most common STRs found in diatoms are DNA 
motifs with a repeat unit of 3 or 6 bases (Table 1; Fig. 1A). Triplet repeats alone 
account for almost one-third of the total STR sequence set (from 29.6 % in P. 
tricornutum to 42.6 % in T. pseudonana); while, together, triplets and hexaplets 
represent more than half of the repeat set. Most of the diatom STRs have up to 5 repeat 
copies, and only a small fraction more than 6 and up to 146 (P. tricornutum: 4.1%; T. 
pseudonana: 4.2%; P. multistriata: 7.7%; F. cylindrus: 13.2%) (Fig. 1B). In all species 
inspected, around half of the STRs has 3 repeat copies (Fig. 1B).  
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Figure 1. Characterization of STRs in diatom genomes. A) STR Distribution by Unit Size;  
B) STR Distribution by Repeat Number. 
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The sequence AAC is the most frequent repeat with a total of 61,199 occurrences 
across all diatoms. AAC occupies the first position in T. pseudonana and in F. 
cylindrus, and the second position in P. tricornutum and in P. multistriata (Table 2). 
This result extends our previous findings that the genome of F. cylindrus is enriched 
in CAA repeats (equivalent to AAC) (Mock et al., 2017). The second most prevalent 
repeat in diatoms is AAG, which is at the second position in T. pseudonana, at the 
third position in P. tricornutum and in P. multistriata, and at the fourth position in F. 
cylindrus, with a total of 43,987 occurrences collectively. Along with repeats that are 
highly frequent in all diatoms, we also found repeats that are at the top position in one 
species only. For instance, ACG is at the first position in P. tricornutum, but at the 
fifth position in P. multistriata and at the sixth position in T. pseudonana and in F. 
cylindrus. Likewise, ACT is at the first position in P. multistriata, but at the fifth, 
eighth and ninth positions in F. cylindrus, T. pseudonana and P. tricornutum, 
respectively. Finally, the AAT repeat is at the third position in F. cylindrus with 32,063 
occurrences but at the very last position in P. tricornutum, T. pseudonana and P. 
multistriata. Taken together our results indicate for the first time that diatom genomes 
are highly enriched in triplet repeats. 
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Table 2. Triplet STRs identified in diatom genomes. 
 Unit Number 
of STRs 
Avg Repeat 
Number 
StdDev Repeat 
Number 
Phobos 
total score 
P. tricornutum  ACG 2,851 3.51 0.86 20,176 
AAC 2,435 3.86 1.94 19,352 
AAG 2,293 3.34 0.78 15,418 
AGC 1,510 3.33 0.65 10,274 
CCG 1,395 3.28 0.55 9,236 
ACC 1,378 3.45 0.85 9,659 
ATC 1,179 3.37 0.87 8,034 
AGG  902 3.36 0.77 6,177 
ACT 781 3.69 1.93 5,750 
AAT 363 3.25 0.62 2,382 
T. pseudonana AAC 9,118 3.94 3.11 72,909 
AAG 6,817 3.43 0.85 47,302 
AGG 6,379 3.56 1 45,831 
ATC 5,925 3.55 0.97 42,873 
AGC 4,336 3.67 1.21 33,056 
ACG 4,336 3.63 0.99 32,016 
ACC 4,149 3.61 1.02 30,461 
ACT 1,337 4.03 7.38 10,229 
CCG 903 3.43 0.71 6,359 
AAT 515 3.17 0.38 3,313 
P. multistriata ACT 16,239 5.29 6.01 175,874 
AAC 12,845 4.42 3.94 116,914 
AAG 9,469 3.58 1.25 67,358 
AGC 8,276 4.07 2.27 68,513 
ACG 6,746 4 1.73 54,984 
ACC 5,838 3.65 1.55 43,735 
AGG 5,507 3.58 1.45 40,123 
ATC 4,288 3.71 3.56 32,075 
CCG 3,371 3.49 0.8 23,949 
AAT 2,100 3.51 1.42 14 847 
F. cylindrus AAC 36,801 4.56 2.24 344,162 
ATC 33,137 4.42 2.24 296,677 
AAT 32,063 4.12 1.96 265,976 
AAG 25,408 4.09 1.78 210,149 
ACT 18,782 4.28 1.88 166,747 
ACG 17,029 4.37 1.92 155,388 
AGC 14,541 4.55 2.22 139,321 
ACC 10,979 4.01 1.51 91,488 
AGG 6,609 3.96 1.54 54,975 
CCG 1,574 3.7 1.06 12,133 
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STRs are abundant in diatom promoters and introns 
 
To further characterize the repeat sequence set, we examined its distribution 
with respect to the genomic features by determining the occurrences of STRs in exons, 
introns, promoters (i.e. the 500 nucleotides upstream of gene TSS features) and 
intergenic regions. We identified highest occupancy in “promoter-TSS” regions in all 
species with the exception of F. cylindrus where STRs are slightly more abundant in 
introns (Fig. 2A). Through the visual inspection of the 20,000 nucleotides centered 
around the TSS of all diatom genes, we confirmed that STRs are preferentially located 
in promoters (Fig. 2B). We also noted that the density of STRs decreases near the gene 
TSS in all species (Fig. 2B). As second category after promoters-TSS, we found a high 
number of STRs in diatom “introns” (Fig. 2A). Further analyses indicated that STRs 
are significantly over-represented in the first introns of genes of T. pseudonana (BH-
FDR adjusted p-value = 2.85 E-14), P. multistriata (BH-FDR adjusted p-value =1.38 
E-13) and F. cylindrus (BH-FDR adjusted p-value = 1.16 E-12), and to some extent of 
P. tricornutum (BH-FDR adjusted p-value = 0.15). Instead there was no significant 
enrichment in the other introns (e.g. BH-FDR adjusted p-value = 1 in non-first introns 
of all diatom species). Finally, after promoters and introns, STRs occupy “exons” as 
third category, and “intergenic regions” as fourth and last category (Fig. 2A). Taken 
together these results show that STRs are very abundant in promoters and introns of 
diatoms and that they generally present the following decreasing order of occupancy: 
promoter-TSS, introns, exons, and intergenic regions.  
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Figure 2. Distribution of STRs in annotated regions. A) Number of STRs located in exons, introns, 
promoter-TSS and intergenic regions. Values are normalized by feature size and reported in kilobases 
(kb). B) STR Distribution within the 20kb region surrounding gene TSS features. 
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Diatom promoters are enriched in AAC repeats 
 
To investigate whether the strong signal in promoters was determined by one 
or more DNA repeat motifs, we refined our search in the 500 bp upstream of each TSS. 
We compared the STR occurrences found in each promoter sequence against those 
measured in a set of 1,000 shuffled sequences to assess the significance of the 
enrichment (Fig. 3A). Over two-thirds of diatom promoters harbor at least one STR, 
ranging from 68.3% promoters in P. tricornutum to 93.5% in F. cylindrus. Like for the 
genome-wide analysis, triplet repeats are very abundant also in promoters representing 
almost one third of the STRs (42,944 out of 147,843 total promoter STRs) (Fig. 3B); 
however, while triplets are the top class in T. pseudonana and in F. cylindrus 
promoters, tetra- and penta-nucleotide repeats are respectively more abundant than 
triplets in P. tricornutum and in P. multistriata promoters (Fig. 3B). Among triplets, 
AAC is the most frequent motif in P. tricornutum, in T. pseudonana and in F. cylindrus 
with a clear and sharp peak before the TSS (Fig. 3C), but not in P. multistriata where 
AGT is at the top (Fig. 3C). Among tetraplets, the top repeats are ACGT in P. 
multistriata, AGCT in P. tricornutum, AAAT in F. cylindrus and AAAC in T. 
pseudonana. The latter is also abundant in F. cylindrus. Among pentaplets, ACCGT 
and ACGGT are most abundant in P. multistriata with 1,512 counts overall (Fig. 3C), 
while other top frequent pentaplets are ACCCT in P. tricornutum, AACAC in T. 
pseudonana and AAAAC in F. cylindrus (Fig. 3C). 
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Figure 3. STR analysis in diatom promoters. A) Selection of promoters for STR analysis. B) 
Distribution of promoter-STRs by Unit Size. 3) Distribution around the TSS features of most frequent 
tri-, tetra- and penta-promoter STRs. 
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We further examined the promoter STRs focusing only on triplets. Hierarchical 
clustering analysis of STR occurrences indicated two similarity groups, with P. 
tricornutum, T. pseudonana and F. cylindrus on one side and P. multistriata alone on 
the other (Fig. 4). For comparison, we obtained similar results on tetraplets. AAC is 
the most statistically over-represented triplet in promoters (BH-FDR adjusted p-value 
= 0 in all diatoms) with a total of 6,088 occurrences (Fig. 4). This motif is at the top 
position in P. tricornutum, in T. pseudonana and in F. cylindrus but only third in P. 
multistriata. The relative distribution of AAC in the 4,000 nucleotides around the TSS 
confirms the strong enrichment in promoters of P. tricornutum, T. pseudonana and F. 
cylindrus (Fig. 3C; Fig. 4).  
 
Figure 4. Heatmap representation of triplet repeat occurrences found in promoters. Rows represent all 
possible triplet repeats; columns represent all the diatom species under investigation. For each species 
(e.g. within each column), a white-to-red color gradient shows the number of STR occurrences (white 
= zero STRs; dark red = highest number of repeat occurrences found in that specific species). 
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Other triplets were highly frequent only in one or two species. For instance, we found 
a specific enrichment of A[CG]T motifs in P. multistriata: AGT was first in P. 
multistriata but fifth, eleventh and eighteenth in P. tricornutum, F. cylindrus and T. 
pseudonana; ACT was second in P. multistriata but sixth, eighth and seventeenth in 
P. tricornutum, F. cylindrus and T. pseudonana. The AGT and ACT motifs together 
account for one-third of all triplets located in P. multistriata promoters (Fig. 4). As 
additional example, GTT was second in P. tricornutum and in T. pseudonana, fourth 
in P. multistriata, but only ninth in F. cylindrus (Fig. 4). Finally, several T and A rich 
motifs were extremely abundant in F. cylindrus promoters (Fig. 4): AAT was second 
in F. cylindrus but ninth in P. multistriata and twentieth in both P. tricornutum and T. 
pseudonana, AAG was fourth in F. cylindrus but eleventh, thirteenth and fifteenth in 
T. pseudonana, P. tricornutum and P. multistriata, and ATT was sixth in F. cylindrus 
but tenth, eighteenth and nineteenth respectively in P. multistriata, P. tricornutum and 
T. pseudonana. Interestingly, we found AAT and ATT triplets significantly 
represented in F. cylindrus promoters (ATT: 1,806 observed vs 564.6 expected with 
BH-FDR adjusted p-value = 0, and AAT: 2,844 observed vs 748.9 expected with BH-
FDR adjusted p-value = 0) and P. multistriata promoters (ATT: 182 observed vs 163.4 
expected with BH-FDR adjusted p-value = 0.066, and AAT: 202 observed vs 165.8 
expected with BH-FDR adjusted p-value = 0.0033), but not in P. tricornutum 
promoters (ATT: 64 observed vs 112.18 expected with BH-FDR adjusted p-value = 1, 
and AAT: 42 observed vs 112.91 expected with BH-FDR adjusted p-value = 1) and T. 
pseudonana promoters (ATT: 93 observed vs 90.4 expected with BH-FDR adjusted p-
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value = 0.41, and AAT: 88 observed vs 110.8 expected with BH-FDR adjusted p-value 
= 0.90).  
Taken together, we conclude that AAC is by far the most prevalent repeat motif in 
diatom promoters, although AGT and ACT are the most abundant triplets in P. 
multistriata promoters (whereas AAC is only third) and AAT and ATT (i.e. TATA-
box like DNA motifs) are very frequent in F. cylindrus promoters. 
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Discussion 
 
The current study presents the first genome-wide catalogue of short repetitive 
elements in lower eukaryotes such as marine diatoms. Because repetitive sequences 
are more difficult to detect using standard high-throughput sequencing technologies 
(Bahlo et al., 2018), the study of short tandem repeats (STRs) has been so far neglected 
compared to the one of single nucleotide polymorphisms (SNPs) and short insertions 
and deletions (InDels). As a result, our collective knowledge of variations in STRs 
remains scarce.  
Recent studies indicated that STRs are located both in genes and in non-coding regions 
(Gemayel et al., 2010; Sawaya et al., 2013). In higher eukaryotic genomes, STRs are 
also found in promoters (Sawaya et al., 2013). The repetitive nature of these sequences 
might induce strand-splippage events in DNA replication resulting in mutations in the 
number of repeats with possible effects on the phenotype. In this light, expansion or 
contraction of promoter STRs might affect gene expression through several possible 
mechanisms: they can form transcription factor binding sites (Contente, Dittmer, 
Koch, Roth, & Dobbelstein, 2002), can alter spacing between regulatory elements 
(Rockman & Wray, 2002), or modulate epigenetics via DNA methylation (Quilez et 
al., 2016). These unstable repetitive elements in promoters are very important as they 
may facilitate evolutionary changes in phenotypes (Gemayel et al., 2010). 
The advent of high-throughput sequencing technologies has enabled the development 
of novel genomic resources. The genome sequences of four marine diatom species 
have been released for public use in recent years. The small genomes of Thalassiosira 
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pseudonana and Phaeodactylum tricornutum were the first ones to be sequenced and 
provided an unprecedented wealth of information about diatom biology and their 
evolution (Armbrust, 2009; Bowler et al., 2008). In addition, the genome sequences of 
Fragilariopsis cylindrus and Pseudo-nitzschia multistriata have recently provided 
insights into genome evolution of diatom species that are adapted to live in extreme 
conditions of the sea ice in the Southern Ocean (Basu et al., 2017; Mock et al., 2017).  
Our genome-wide analysis reveals for the first time that the genomes of these 
unicellular photosynthetic eukaryotes are rich in triplet repeats that are mostly located 
in non-coding regions, particularly in promoters. This finding is novel and is confirmed 
in all four diatoms regardless of their genome size. Promoter repeats are very abundant 
within the 500 nucleotides upstream of the gene TSS features and comprise over-
represented DNA motifs. Overall, AAC is the most statistically over-represented 
triplet in promoters. This motif is at the top position in P. tricornutum, in T. 
pseudonana and in F. cylindrus but only third in P. multistriata. Noteworthy, AGT 
and ACT are the most abundant triplets in P. multistriata promoters, while AAT and 
ATT (TATA-box like DNA motifs) are also very frequent in F. cylindrus promoters.  
We hypothesize that the significant enrichments of STRs in the promoters of diatoms 
might be important for the regulation of transcription. Based on this assumption, we 
are currently testing some of these genomic elements to understand if different number 
of copies of the simple repeats into STRs might modulate transcriptional levels. From 
what we are learning from the sex locus of Pseudo-nitzschia multistriata it is evident 
that STRs are at least linked to specific gene expression (Russo et al, in revision). In 
order to prove the molecular function of these hypothetic regulatory sequences, we 
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selected promoters of genes of interest for a modular cloning analysis in 
Phaeodactylum tricornutum cells (Table 3).  
 
Promoter ID Gene ID, Description STR 
Star
t  
STR 
End  
Uni
t 
Size 
Repeat 
Numbe
r 
Repeat 
Unit 
 
Perfectio
n 
32_76837_77337_+ Phatr3_J50610, Predicted protein  342 436 3 31.667 AAC 100 
bd_31x35_90668_91168_
+ 
Phatr3_EG02359, MPDC (mevalonate 
diphosphate decarboxylase) 
415 457 2 21.5 CT 97.674 
bd_31x35_90668_91168_
+ 
Phatr3_EG02359, MPDC (mevalonate 
diphosphate decarboxylase) 
461 481 2 10.5 AC 95.238 
bd_31x35_90633_91133_- Phatr3_EG02362, POLA (DNA 
polymerase) 
10 52 2 21.5 AG 97.674 
bd_31x35_90633_91133_- Phatr3_EG02362. POLA (DNA 
polymerase) 
450 490 3 13.333 AAC 92.5 
 
Table 3. Promoter STRs selected for modular cloning analysis. 
 
 
First, we chose the promoter of the gene Phatr3_J50610 which is perhaps the most 
important for several reasons: 1) it contains the longest STR with the repeat AAC 
which also very significant in many other diatom species, therefore testing this 
promoter might give us useful information on STRs in diatoms in general; 2) it is long 
and there are variations in its length reported in Ensembl which means that there exists 
several alleles and therefore it could be easy to validate the regulatory activity of the 
reference sequence as well as of the other alleles. Second, the promoter of the 
gene Phatr3_EG02362 which is annotated as DNA polymerase gene and has a STR of 
decent length. Third, the promoter of the gene Phatr3_EG02359 which is annotated as 
the mevalonate diphosphate decarboxylase (MPDC), a gene involved in the isoprenoid 
synthesis, and has a STR of good size. It is also important to note that these two genes, 
Phatr3_EG02362 and Phatr3_EG02359, are located in the same genomic region and 
positioned head-to-head. The intergenic region between these two head-to-head genes 
is also of interest for the several reasons: 1) it is rather small and therefore easily to 
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handle in the lab; 2) one of the genes should be expressed in many conditions at high 
levels (POLA) while the other should be more finely regulated; 3) in the case in which 
STRs have a regulatory function we do not know whether the strand is important in 
the directing the transcription and this region could be helpful in understanding; 4) it 
contains more than one type of STRs. In conclusion, this region is small but complex, 
and it would give us different information compared to the promoter region of the 
Phatr3_J50610 gene which is simpler.  
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Appendix. Code Example: tandem_repeat_analysis.pl 
#! /usr/bin/perl -w 
 
=head1 NAME 
 
=head1 SYNOPSIS 
 
  perl tandem_repeat_analysis.pl [-s species_name] [-g genome_FASTA] [-a 
annotation_GTF] [-c chr_sizes] [-nc_rna] [-cds] [-d source] [-force] [-h help] 
 
=head1 DESCRIPTION 
 
This script identifies and annotates tandem repeats from an entire genome sequence.  
 
It requires a genomic sequence in FASTA format and related annotation in GTF format. 
 
Typical usage is as follows: 
 
  % perl tandem_repeat_analysis.pl -s Phaeodactylum_tricornutum -g 
Phaeodactylum_tricornutum.ASM15095v2.29.dna.toplevel.fa -a 
Phaeodactylum_tricornutum.ASM15095v2.29.gtf -c Phaeodactylum_tricornutum.chrsizes.txt 
   
=head2 Options 
 
The following options are accepted: 
 
 --s=<species name> Specify the species name. 
 
 --g=<genome fasta> Specify genome sequence in FASTA format. 
 
 --a=<annotation gtf> Specify annotation file name if any. GTF format is required. 
 
 --c=<chr sizes>    Provide a file containing chromosome sizes 
 
 --nc_rna    Consider ncRNAs, if defined. 
 
 --cds                 Build TSS, TTS and promter features using CDS coordinates 
(instead of gene), if defined. 
 
 --d=<source>  Source (ensembl, jgi or internal). 
 
 --force    Re-load annotation. 
 
 --help   This documentation. 
 
=head1 AUTHOR 
 
Guglielmo Roma 
 
guglielmo.roma@gmail.com 
 
=cut 
 
use Cwd 'abs_path'; 
use File::Basename; 
my ($name,$path,$suffix) = fileparse(abs_path($0)); 
require $path."../conf/conf.pl"; 
 
use strict; 
use warnings; 
use Getopt::Long qw( :config posix_default bundling no_ignore_case ); 
use Pod::Usage; 
use Data::Dumper; 
 
# Configuration variables 
 
my %conf =  %::conf; 
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my $debug = $conf{'global'}{'debug'}; 
my $tmp_dir = $conf{'default'}{'tmp_dir'}; 
my $genomes_dir = $conf{'default'}{'genomes_dir'}; 
my $bioinfo_dir = $conf{'default'}{'bioinfo_dir'}; 
my $results_dir = $conf{'default'}{'results_dir'}; 
my %species_hash = %{$conf{'species'}}; 
 
my $PHOBOS = $conf{'PHOBOS'}{'command_genome'}; 
my $MaxPeriod = $conf{'PHOBOS'}{'MaxPeriod'}; 
 
# Functions declarations 
 
=pod 
   
 SCRIPT 
  
=cut 
 
my $USAGE = "perl tandem_repeat_analysis.pl [-s species_name] [-g genome_FASTA] [-a 
annotation_GTF] [-c chr_sizes] [-nc_rna] [-cds] [-d source] [-force] [-h help]"; 
 
my ($species_name, $genome_fasta, $annotation_gtf, $chr_sizes, $cds, $nc_rna, $force, 
$source, $show_help); 
 
&GetOptions(      
   'species_name|s=s' => \$species_name, 
   'genome_fasta|g=s' => \$genome_fasta, 
   'annotation_gtf|a=s' => \$annotation_gtf, 
   'chr_sizes|c=s'  => \$chr_sizes, 
                 'source|d=s'       => \$source, 
   'nc_rna'   => \$nc_rna, 
   'cds'                  => \$cds, 
   'force'   => \$force, 
   'help|h'          => \$show_help 
   ) 
  or pod2usage(-verbose=>2); 
pod2usage(-verbose=>2) if $show_help; 
 
# Considers user-specified options - if provided  
if ($species_name && $genome_fasta && $annotation_gtf && $chr_sizes && $source) { 
 # Overwrites default options from the configuration file 
 undef(%species_hash); 
 $species_hash {$species_name} {'genome_FASTA'} = $genome_fasta; 
 $species_hash {$species_name} {'annotation_GTF'} = $annotation_gtf; 
 $species_hash {$species_name} {'chrsizes'} = $chr_sizes; 
        $species_hash {$species_name} {'source'} = $source; 
} 
 
# Dies, if users did not specify a species of interest in either command line or the 
config file 
die "You must specify a species name, a genome FASTA file, and an annotation file\n 
Use -h for help" 
   if (!%species_hash); 
 
$cds=0 if(!$cds); 
 
$debug && print STDOUT "Debugging species hash:\n"; 
$debug && print STDOUT Dumper %species_hash; 
$debug && print STDOUT "\n"; 
 
#my $tmp_bed = $tmp_dir."/bed"; 
#mkdir($tmp_bed or die "$!"); 
 
foreach $species_name (keys %species_hash) { 
 $genome_fasta = $species_hash{$species_name}{'genome_FASTA'}; 
 $annotation_gtf = $species_hash{$species_name}{'annotation_GTF'}; 
 $chr_sizes = $species_hash{$species_name}{'chrsizes'}; 
      $source = $species_hash{$species_name}{'source'}; 
 
 $debug && print STDOUT "Species: $species_name\n"; 
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 $debug && print STDOUT "FASTA: $genome_fasta\n";   
 $debug && print STDOUT "GTF: $annotation_gtf\n";   
 $debug && print STDOUT "CHRSizes: $chr_sizes\n";   
 $debug && print STDOUT "Source: $source\n"; 
 
 # Creates a result folder for each species 
 my $now_string = localtime; 
 $now_string =~ s/\W/_/g; 
 my ($gender, $species) = split/["_","."]/, $genome_fasta; 
 my $short_species_name = lc(substr($gender, 0, 1).".".$species); 
 my $result_path = $results_dir.$short_species_name."_".$now_string; 
 mkdir($result_path) or die "$!"; 
 chdir($result_path) or die "$!"; 
 
 # Executes PHOBOS 
 my $TR_result_file=join('.', $genome_fasta, "dat"); 
 print ("$PHOBOS $genomes_dir/$genome_fasta $result_path/$TR_result_file\n"); 
 system ("$PHOBOS $genomes_dir/$genome_fasta $result_path/$TR_result_file"); 
  
 # Parses PHOBOS output and lists TRs in BED format 
 print ("perl $path/perl/parsing_dat.pl $result_path/$TR_result_file\n"); 
 system ("perl $path/perl/parsing_dat.pl $result_path/$TR_result_file"); 
  
 # Generates TR distribution plots 
 print ("awk '{if(\$4)print \$4}' $result_path/$TR_result_file".".txt | sort -n 
>  $result_path/$TR_result_file".".txt.sort\n"); 
 system ("awk '{if(\$4)print \$4}' $result_path/$TR_result_file".".txt | sort -n 
>  $result_path/$TR_result_file".".txt.sort"); 
 print "R --slave --args $result_path/$TR_result_file".".txt.sort \"Distribution 
of Tandem Repeats ($gender $species)\" $MaxPeriod < $path/R/draw_TR_dist.r\n"; 
 system ("R --slave --args $result_path/$TR_result_file".".txt.sort 
\"Distribution of Tandem Repeats ($gender $species)\" $MaxPeriod < 
$path/R/draw_TR_dist.r"); 
 
 # removing the header line 
 print ("sed 1d $result_path/$TR_result_file.bed > 
$result_path/$TR_result_file.nh.bed\n"); 
 system ("sed 1d $result_path/$TR_result_file.bed > 
$result_path/$TR_result_file.nh.bed"); 
 
 # Annotates non-redundant TRs 
 my $annotate_cmd = "perl $path/annotate.pl -f 
$result_path/$TR_result_file.nh.bed -a $genomes_dir/$annotation_gtf -c 
$genomes_dir/$chr_sizes "; 
 $annotate_cmd .= " --nc_rna" if ($nc_rna); 
 $annotate_cmd .= " --force" if ($force); 
 $annotate_cmd .= " --cds" if ($cds); 
 $annotate_cmd .= " --source $source" if ($source); 
 print STDOUT ($annotate_cmd."\n"); 
 system ($annotate_cmd); 
 
 $debug && print "\nTandem repeat analysis for $species_name complete!\n"; 
} 
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Appendix. Code Example: annotate.pl 
#! /usr/bin/perl -w 
 
=head1 NAME  
 
  annotate.pl 
 
=head1 SYNOPSIS 
 
  perl annotate.pl [-f feature_BED] [-a annotation_GTF] [-c chr_sizes] [-nc_rna] [-
cds] [-so source] [-force] [-h help] 
 
=head1 DESCRIPTION 
 
This script i) creates promoter, TSS and TTS annotation features, ii) annotates 
features of interest provided in BED format using the annotation features. 
 
Typical usage is as follows: 
 
  % perl tandem_repeats/scripts/annotate.pl -f features.bed -a species.gtf -c 
species.chrsizes.txt --nc_rna --force --source ensembl 
   
=head2 Options 
 
The following options are accepted: 
 
 --f=<feature bed> Specify file with genomic features. "6 fields" BED format 
required. 
 
 --a=<annotation gtf> Specify annotation file name if any. GTF format is required. 
 
 --c=<chr sizes>    Provide a file containing chromosome sizes. 
 
 --nc_rna    Consider ncRNAs, if defined. 
 
 --cds                 Build TSS, TTS and promter features using CDS coordinates 
(instead of gene), if defined. 
 
 --source   Annotation source (ensembl, jgi or internal). 
 
 --force    Re-load annotation. 
 
 --help   This documentation. 
 
=head1 AUTHOR 
 
Guglielmo Roma 
 
guglielmo.roma@gmail.com 
 
=cut 
 
use Cwd 'abs_path'; 
use File::Basename; 
my ($name,$path,$suffix) = fileparse(abs_path($0)); 
require $path."../conf/conf.pl"; 
 
use strict; 
use warnings; 
use Getopt::Long qw( :config posix_default bundling no_ignore_case ); 
use Pod::Usage; 
use Data::Dumper; 
use File::Spec::Functions qw(catfile rootdir); 
use List::Util qw[min max]; 
use File::Temp qw/ :POSIX /; 
 
# Configuration variables 
 70 
 
my %conf =  %::conf; 
my $debug = $conf{'global'}{'debug'}; 
my $promoter_sizes = $conf{'global'}{'promoter_sizes'}; 
my %promoter_sizes = %{$promoter_sizes}; 
my $transcript_feature_types = $conf{'global'}{'transcript_feature_types'}; 
my %transcript_feature_types = %{$transcript_feature_types}; 
my @transcript_feature_types = values %transcript_feature_types; 
 
# Functions declarations 
 
=pod 
   
 SCRIPT 
  
=cut 
 
my $USAGE = "perl annotate.pl [-f feature_BED] [-a annotation_GTF] [-c chr_sizes] [-
nc_rna] [-cds] [-so source] [-force] [-h help]"; 
 
my ($feature_bed, $annotation_gtf, $chr_sizes, $nc_rna, $cds, $source, $force, 
$show_help); 
 
&GetOptions(      
   'feature_bed|f=s'  => \$feature_bed, 
   'annotation_gtf|a=s' => \$annotation_gtf, 
   'chr_sizes|c=s'  => \$chr_sizes, 
                  'cds'   => \$cds, 
   'nc_rna'   => \$nc_rna, 
   'source|so=s'  => \$source, 
   'force'   => \$force, 
   'help|h'          => \$show_help 
   ) 
  or pod2usage(-verbose=>2); 
pod2usage(-verbose=>2) if $show_help; 
 
# Dies if files are not provided 
die "You must specify an feature file in bed format\n Use -h for help" 
  if !$feature_bed; 
 
die "You must specify an annotation file in gtf format\n Use -h for help" 
  if !$annotation_gtf; 
 
die "You must specify a chr_sizes file\n Use -h for help" 
  if !$chr_sizes; 
 
die "You must specify a source (ensembl, jgi, or internal)\n Use -h for help" 
  if !$source; 
 
$cds = 0 if(!$cds); 
   
# Checks if TSS and TTS files are already created 
my ($ann_name, $ann_path, $ann_suffix) = fileparse($annotation_gtf); 
 
# Defines annotation file names 
my $promoter_file   = $annotation_gtf.".promoter"; 
my $tss_file    = $annotation_gtf.".tss"; 
my $tts_file    = $annotation_gtf.".tts"; 
my $exon_file    = $annotation_gtf.".exon"; 
my $intron_file                    = $annotation_gtf.".intron"; 
my $gene_file    = $annotation_gtf.".gene"; 
 
$debug && print STDOUT "Using $annotation_gtf to create promoter, TSS, TTS and exon 
features.\n"; 
 
# Creates promoter features 
foreach my $promoter_id (keys %promoter_sizes) { 
 my $promoter_size = $promoter_sizes {$promoter_id}; 
 
 if (-e $promoter_file."_".$promoter_size && !defined($force)) { 
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  $debug && print STDOUT "Promoter features are available. Skipping the 
build. Use --force option to reload the annotation.\n"; 
 
 } else { 
  $debug && print STDOUT "Creating promoter features with size 
$promoter_size... "; 
    
  system("rm ".$promoter_file."_".$promoter_size); 
 
  my $cmd; 
  if ($cds==0){ 
   $cmd = 'awk \'{FS="\t";OFS="\t"}{if ($3=="gene") {if ($7=="+") 
{print $1,$2,"promoter_'.$promoter_size.'",$4,$4,$6,$7,$8,$9;} else if($7 == "-"){ 
print $1,$2,"promoter_'.$promoter_size.'",$5,$5,$6 
,$7,$8,$9}}}\' '.$annotation_gtf.' | slopBed -g '.$chr_sizes.' -i stdin -l 
'.$promoter_size.' -r 0 -s |  awk \'{if ($4 >= "0" && $5 >= "0" && $5-
$4=='.$promoter_size.') print $_;}\' > '.$promoter_file."_".$promoter_size; 
  } else{ 
   $cmd = 'awk \'{FS="\t";OFS="\t"}{if ($3=="CDS") {if ($7=="+") 
{print $1,$2,"promoter_'.$promoter_size.'",$4,$4,$6,$7,$8,$9;} else if($7 == "-"){ 
print $1,$2,"promoter_'.$promoter_size.'",$5,$5,$6, 
$7,$8,$9}}}\' '.$annotation_gtf.' | slopBed -g '.$chr_sizes.' -i stdin -l 
'.$promoter_size.' -r 0 -s |  awk \'{if ($4 >= "0" && $5 >= "0" && $5-
$4=='.$promoter_size.') print $_;}\' > '.$promoter_file."_".$promoter_size; 
  }  
 
  system($cmd); 
                $debug && print STDOUT $cmd."\n"; 
  
  $debug && print STDOUT "Done!\n"; 
 }  
} 
 
# Creates TSS, TTS and EXON features 
if (-e $tss_file && !defined($force)) { 
 
 $debug && print STDOUT "TSS, TTS, EXON and GENE features are available. 
Skipping the build. Use --force option to reload the annotation.\n";  
 
} else { 
 $debug && print STDOUT "Creating TSS, TTS, EXON and GENE features... "; 
 
 my ($TSS_list, $TTS_list, $exon_list, $gene_list); 
 
 open (FILE, $annotation_gtf) or die "Cannot open $annotation_gtf: $!"; 
  
 while (my $row = <FILE>) { 
  chomp ($row); 
   
  if ($row  !~ /^#/) { 
   my @fields =  split(/\t/, $row); 
 
   my $cmd; 
                  
   if ($cds==0){ 
    $gene_list .= "$row\n" if ($fields[2] eq "gene"); 
   } else { 
    $gene_list .= "$row\n" if ($fields[2] eq "CDS"); 
   } 
   $exon_list .= "$row\n" if ($fields[2] eq "exon"); 
    
   my ($start_promoter, $TSS, $TTS); 
 
   # Retrieves only transcript feature types that are predefined in 
the config file 
   next unless ((grep {$_ eq $fields[2]} @transcript_feature_types) || 
($cds && $fields[2] eq "CDS")); 
 
   if ($fields[6] eq "+") { 
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    $TSS = min($fields[3], $fields[4]);  
    $TTS = max($fields[3], $fields[4]); 
      
   } else { 
    
    $TSS = max($fields[3], $fields[4]);  
    $TTS = min($fields[3], $fields[4]);  
    
   } 
    
   $fields[3] = $TSS; 
   $fields[4] = $TSS; 
 
   $TSS_list .= join("\t", @fields)."\n"; 
    
   $fields[3] = $TTS; 
   $fields[4] = $TTS; 
 
   $TTS_list .= join("\t", @fields)."\n"; 
  } 
 } 
  
 close FILE; 
 
 open (TSS, ">$tss_file"); 
 print TSS "$TSS_list"; 
 close (TSS);  
  
 open (TTS, ">$tts_file"); 
 print TTS "$TTS_list"; 
 close (TTS);  
 
 open (EXON, ">$exon_file"); 
 print EXON "$exon_list"; 
 close (EXON);  
 
 open (GENE, ">$gene_file"); 
 print GENE "$gene_list"; 
 close (GENE);  
 
 # create intron features 
 my $annotype = 'ensembl'; 
 my $exon_sort_cmd = "sort -n -k1 -k4 $exon_file > $exon_file".".sort"; 
 my $reformat_cmd = "perl  $path/perl/reformatGTF_forintronsize.pl 
$exon_file".".sort $source"; 
 my $intron_cmd = "perl $path/genomegtf2intronbed.pl -gtf $annotation_gtf > 
$intron_file"; 
 my $intron_sort_cmd = "sort -n -k1 -k4 $intron_file > $intron_file".".sort"; 
 my $merge_introns_cmd = "bedtools merge -i $intron_file".".sort >  
$intron_file".".sort.nr.bed"; 
 my $intron_size_cmd = 'awk \'{sum += ($3-$2+1)} END {print sum}\' 
'.$intron_file.'.sort.nr.bed > '.$intron_file.".size"; 
 
 system ($exon_sort_cmd); 
 system ($exon_sort_cmd); 
 system ($reformat_cmd); 
 system ($intron_cmd); 
 system ($intron_sort_cmd); 
 system ($merge_introns_cmd); 
 system ($intron_size_cmd); 
 
 $debug && print STDOUT "Done!\n"; 
} 
 
foreach my $promoter_id (keys %promoter_sizes) { 
 my $promoter_size = $promoter_sizes {$promoter_id}; 
 
 # Overlapping annotation features 
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 my $overlapping_anno_cmd = "intersectBed -a $feature_bed -b $tss_file -c | 
intersectBed -a stdin -b $promoter_file"."_"."$promoter_size -c | intersectBed -a 
stdin -b $tts_file -c | intersectBed -a stdin -b $exon_ 
file -c | intersectBed -a stdin -b $intron_file -c | intersectBed -a stdin -b 
$annotation_gtf -c | uniq > $feature_bed"."_".$promoter_size."anno.txt"; 
 $debug && print STDOUT ("$overlapping_anno_cmd\n"); 
 system ($overlapping_anno_cmd); 
 
 my $parse_overlapping_anno_cmd = "perl $path/perl/parse_annotation.pl 
$feature_bed"."_".$promoter_size."anno.txt | sort | uniq -c | sort -nr > 
/$feature_bed"."_".$promoter_size."anno.stats.txt"; 
  $debug && print STDOUT ("$parse_overlapping_anno_cmd"); 
 system ($parse_overlapping_anno_cmd); 
 
 my $pie_plot_cmd = "R --slave --args 
$feature_bed"."_".$promoter_size."anno.stats.txt \"Tandem Repeat annotation\" < 
$path/R/draw_annotation_pie.r "; 
 $debug && print STDOUT ($pie_plot_cmd); 
 system ($pie_plot_cmd); 
} 
 
# Overlapping gene features (for genic vs intergenic plot) 
my $genic_anno_cmd = "intersectBed -a $feature_bed -b $gene_file -c | uniq > 
$feature_bed"."_gene_anno.txt"; 
$debug && print STDOUT ("$genic_anno_cmd\n"); 
system ($genic_anno_cmd); 
 
my $genic_anno_stat_cmd = "perl $path/perl/parse_gene_annotation.pl 
$feature_bed"."_gene_anno.txt | sort | uniq -c | sort -nr > 
/$feature_bed"."_gene_anno.stats.txt"; 
$debug && print STDOUT ("$genic_anno_stat_cmd\n"); 
system ($genic_anno_stat_cmd); 
 
my $pie_gene_plot_cmd = "R --slave --args $feature_bed"."_gene_anno.stats.txt 
\"Tandem Repeat annotation\" < $path/R/draw_annotation_pie.r "; 
$debug && print STDOUT ("$pie_gene_plot_cmd\n"); 
system ($pie_gene_plot_cmd); 
 
# Overlapping exon features (for exonic vs non-exonic plot) 
my $exonic_anno_cmd = "intersectBed -a $feature_bed -b $exon_file -c | uniq > 
$feature_bed"."_exonic_anno.txt"; 
$debug && print STDOUT ("$exonic_anno_cmd\n"); 
system ($exonic_anno_cmd); 
 
my $exonic_anno_stat_cmd = "perl $path/perl/parse_exonic_annotation.pl 
$feature_bed"."_exonic_anno.txt | sort | uniq -c | sort -nr > 
/$feature_bed"."_exonic_anno.stats.txt"; 
$debug && print STDOUT ("$exonic_anno_stat_cmd\n"); 
system ($exonic_anno_stat_cmd); 
 
my $pie_exonic_plot_cmd = "R --slave --args $feature_bed"."_exonic_anno.stats.txt 
\"Tandem Repeat annotation\" < $path/R/draw_annotation_pie.r "; 
$debug && print STDOUT ("$pie_exonic_plot_cmd\n"); 
system ($pie_exonic_plot_cmd); 
 
# Computes the distance of each feature to the closest TSS.  
my $closest_TSS_dist_cmd = "closestBed -D b -t first -a $feature_bed -b ".$tss_file." 
| awk '{print \$NF}' > "."$feature_bed.tss.dist.txt"; 
$debug && print STDOUT ("$closest_TSS_dist_cmd\n"); 
system ($closest_TSS_dist_cmd); 
 
# Generates a plot with the distance of each feature to the closest TSS.  
my $closest_TSS_dist_plot_cmd = "R --slave --args $feature_bed.tss.dist.txt 
\"Distribution of Tandem Repeats around TSS\" < $path/R/draw_TSS_linear_dist-
4kb_50b.r "; 
system ($closest_TSS_dist_plot_cmd); 
$debug && print STDOUT ("$closest_TSS_dist_plot_cmd\n"); 
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my $closest_TSS_dist_plot_cmd2 = "R --slave --args $feature_bed.tss.dist.txt 
\"Distribution of Tandem Repeats around TSS\" < $path/R/draw_TSS_linear_dist-
400b_10b.r "; 
system ($closest_TSS_dist_plot_cmd2); 
$debug && print STDOUT ("$closest_TSS_dist_plot_cmd2\n"); 
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Chapter III 
 
A comparative transcriptomic analysis of replicating and 
dormant liver stages of the relapsing malaria parasite 
Plasmodium Cynomolgi 
 
Abstract  
 
Plasmodium liver hypnozoites, which cause disease relapse, are widely 
considered to be the last barrier towards malaria eradication. The biology of this 
quiescent form of the parasite is poorly understood which hinders drug discovery. We 
report a comparative transcriptomic dataset of replicating liver schizonts and dormant 
hypnozoites of the relapsing parasite Plasmodium cynomolgi. Hypnozoites express 
only 34% of Plasmodium physiological pathways, while 91% are expressed in 
replicating schizonts. Few known malaria drug targets are expressed in quiescent 
parasites, but pathways involved in microbial dormancy, maintenance of genome 
integrity and ATP homeostasis were robustly expressed. Several transcripts encoding 
heavy metal transporters were expressed in hypnozoites and the copper chelator 
neocuproine was cidal to all liver stage parasites. This transcriptomic dataset is a 
valuable resource for the discovery of vaccines and effective treatments to combat 
vivax malaria. 
 
  
 76 
Introduction  
 
Plasmodium vivax (P. vivax) is the major cause of malaria outside of Africa 
with an estimated 13.8 million malaria cases globally in 2015 (World Health 
Organization (WHO), 2015). Among P. vivax parasites’ most salient biological 
features are the persisting dormant liver stages (hypnozoites) that can cause relapse 
infections and compromise future eradication programs (Campo, Vandal, Wesche, & 
Burrows, 2015). Although in vitro hepatic cultures systems for hypnozoite-forming 
parasites have been developed (March et al., 2013; Zeeman et al., 2014) and rodent 
models of humanized liver stage infections constituted recent advances (Mikolajczak 
et al., 2015), the search for new drugs targeting hypnozoites is hampered by our limited 
knowledge of this enigmatic dormant stage.  
Microbes commonly employ cellular quiescence to survive environmental stresses 
such as starvation, immune surveillance, or chemotherapeutic interventions and for 
disease causing microbes, dormancy often underlies chronic infections that 
considerably complicate the clinical management of infected patients (Rittershaus, 
Baek, & Sassetti, 2013). Cellular quiescence generally requires a physiological 
response underscored by a global repression of cellular metabolism but the 
preservation of mitochondrial respiration for ATP homeostasis and the maintenance 
of genome integrity (Rittershaus et al., 2013). Therapeutic interventions targeting 
some of these mechanisms have been proposed for a limited number of human 
pathogens (Andries et al., 2005; Rao, Alonso, Rand, Dick, & Pethe, 2008) but it is not 
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clear whether P. vivax hypnozoites rely on similar physiological responses to survive 
in hepatocytes. 
Some of the new drug targets that have been identified in the past decade (C. 
McNamara & Winzeler, 2011) have been shown to be critical in multiple stages of the 
parasite life cycle, such as PI4K (C. W. McNamara et al., 2013), DHODH (Phillips et 
al., 2015), eEF2 (Baragana et al., 2015), and pheT-RNA (Kato et al., 2016). However, 
none has yet been shown to be a valid target for malaria radical cure and elimination 
of the hypnozoite in vivo. Little is known about the expression pattern of these drug 
targets during Plasmodium life cycle in the liver and more specifically, it is not clear 
whether these genes are expressed at all in dormant parasites. 
Transcriptomics approaches to assess genome-wide gene expression levels of 
Plasmodium liver stage parasites are inherently challenging given the low infection 
grade ratios and the higher abundance of host cell transcripts. While previous reports 
have emerged providing a first glance of gene expression in Plasmodium liver stages 
(Cubi et al., 2017; Vaughan et al., 2009), we provide here a comprehensive dataset 
derived from green fluorescent protein (GFP)-tagged Plasmodium cynomolgi (P. 
cynomolgi) (Voorberg-van der Wel et al., 2013) — the nonhuman primate sister taxon 
of P. vivax, known to form hypnozoites (Dembélé et al., 2014; Krotoski et al., 1982). 
We have collected samples from multiple independent in vitro hepatocyte infections, 
containing thousands of purified hypnozoites and liver schizonts for RNA-Seq. The 
sequenced reads were mapped on the new high quality, completely annotated P. 
cynomolgi genome covering 7,178 genes (Pasini et al., 2017). Using different 
approaches, we provide some preliminary validation of our comparative analysis of 
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the transcriptome of replicating and quiescent liver-stages parasites, that will constitute 
a valuable resource for the development of P. vivax vaccines and therapeutics. 
 
Material and methods  
 
Ethics statement  
 
Nonhuman primates were used because no other models (in vitro or in vivo) 
were suitable for the aims of this project. The local independent ethical committee 
constituted conform Dutch law (BPRC Dier Experimenten Commissie, DEC) 
approved the research protocol (agreement number DEC# 708) prior to the start and 
the experiments were all performed according to Dutch and European laws. The 
Council of the Association for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC International) has awarded BPRC full accreditation. Thus, BPRC is 
fully compliant with the international demands on animal studies and welfare as set 
forth by the European Council Directive 2010/63/EU, and Convention ETS 123, 
including the revised Appendix A as well as the ‘Standard for humane care and use of 
Laboratory Animals by Foreign institutions’ identification number A5539-01, 
provided by the Department of Health and Human Services of the United States of 
America’s National Institutes of Health (NIH) and Dutch implementing legislation. 
The rhesus monkeys (Macaca mulatta, either gender, age 4-7 years, Indian or mixed 
origin) used in this study were captive-bred and socially housed. Animal housing was 
according to international guidelines for nonhuman primate care and use. Besides their 
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standard feeding regime, and drinking water ad libitum via an automatic watering 
system, the animals followed an environmental enrichment program in which, next to 
permanent and rotating non-food enrichment, an item of food-enrichment was offered 
to the macaques daily. All animals were monitored daily for health and discomfort. 
All intravenous injections and large blood collections were performed under ketamine 
sedation, and all efforts were made to minimize suffering. Liver lobes were collected 
from monkeys that were euthanized in the course of unrelated studies (ethically 
approved by the BPRC DEC) or euthanized for medical reasons, as assessed by a 
veterinarian. Therefore, none of the animals from which liver lobes were derived were 
specifically used for this work, according to the 3Rrule thereby reducing the numbers 
of animals used. Euthanasia was performed under ketamine sedation (10 mg/kg) and 
was induced by intracardiac injection of euthasol 20%, containing pentobarbital.  
 
Transgenic Plasmodium cynomolgi sporozoite production  
 
Blood stage infections were initiated in rhesus monkeys by intravenous 
injection of 1x106 P. cynomolgi M strain PcyC-PAC-GFPhsp70-mCherryef1α (Voorberg-
van der Wel et al., 2013)  parasites from a cryopreserved stock. To exclude possible 
wild type contaminant parasites, monkeys were treated with pyrimethamine (1 mg/kg, 
orally on a biscuit every other day) for 3-4 times starting one day post infection. 
Parasitemia was monitored by Giemsa-stained smears prepared from a drop of blood 
obtained from thigh pricks. Animals were trained to voluntarily present for thigh 
pricks, and were rewarded afterwards. Around peak parasitemia, on two consecutive 
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days, generally at days 11 and 12 post-infection, 9 ml of heparin blood was taken to 
feed mosquitoes and monkeys were cured from Plasmodium infection by 
intramuscular treatment with chloroquine (7.5 mg/kg) on three consecutive days. 
Typically ± 600 mosquitoes (two to five days old female Anopheles stephensi 
mosquitoes Sind-Kasur strain Nijmegen; Nijmegen UMC St. Radboud, Department of 
Medical Microbiology) were fed per blood sample using a glass feeder system. 
Mosquitoes were kept under standard conditions (Voorberg-van der Wel et al., 2013). 
Approximately one week after feeding, oocysts were counted and mosquitoes were 
given an uninfected blood meal to promote sporozoite invasion of the salivary glands. 
Mosquitoes that had received blood from the first bleeding ('feed 1') were kept 
separately and treated independently from mosquitoes that had received blood from 
the second bleeding ('feed 2'). 
 
Primary hepatocytes  
 
Primary hepatocytes from Macaca mulatta or Macaca fascicularis were 
isolated freshly as described before or thawed from frozen stocks and resuspended in 
William's B medium (Zeeman et al., 2014): William’s E with glutamax containing 
10% human serum (A+), 1% MEM non-essential amino acids, 2% 
penicillin/streptomycin, 1% insulin/transferrin/selenium, 1% sodium pyruvate, 50 µM 
β-mercapto-ethanol, and 0.05 µM hydrocortisone. Hepatocytes were seeded into 
collagen coated (5 µg/cm2 rat tail collagen I, Invitrogen) 6-well Costar plates at a 
concentration of approximately 2.25×106 cells/well. Following attachment, the 
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medium was replaced by William’s B containing 2 % dimethylsulfoxide (DMSO) to 
prevent hepatocyte dedifferentiation.  
 
Sporozoite isolation and inoculation  
 
Two weeks post mosquito feeding on transgenic P. cynomolgi M strain infected 
blood, salivary gland sporozoites were isolated and used for hepatocyte inoculation. 
Prior to inoculation, hepatocytes were washed in William's B medium followed by 
sporozoite inoculation at ± 2 x 106 sporozoites per well. Plates were spun at RT at 500 
g for 10-20 min and placed in a humidified 37 °C incubator at 5% CO2 for 2-3 h to 
allow for sporozoite invasion. Medium (William's B) was replaced and incubation 
continued. Subsequently, infected hepatocytes were cultured with regular (every other 
day) medium changes until cell sorting. Sporozoite isolations and hepatocyte 
inoculations from 'feed 1' mosquitoes were performed separately from 'feed 2' 
mosquitoes. 
 
Flow cytometry and cell sorting  
 
At day 6 post sporozoite inoculation hepatocytes were harvested by Trypsin 
treatment (0.25% Trypsin-EDTA, Gibco). For logistical reasons, samples PAC22F1 
and PAC22F2 were cultured for an additional day and were trypsinized at day 7 post-
inoculation. Cells were washed once with PBS, followed by 3 min incubation in 
trypsin at 37 °C. Complete William's B medium was added to stop the trypsin 
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digestion, cells were collected and washed two times in William's B medium that was 
diluted 1:5 in William's E to decrease the amount of serum in the samples. Prior to 
sorting, cells were passed through a 100 µM cell strainer to exclude clumps. First, a 
sample of uninfected hepatocytes was analysed to enable gate settings. Subsequently, 
infected hepatocytes were sorted with a BD FACSAria flowcytometer equipped with 
a 488 nm Coherent® Sapphire™ solid state 20 mW Laser. Data analyses were 
performed using FlowJo Version 9.4.10 (TreeStar, Inc., Ashland OR, USA). The 
device was equipped with a 100 µM nozzle for sorting. Gate settings were essentially 
the same as reported previously, except that an extra gate ('GFPdim') was included to 
ensure a strict separation of 'GFPlow' and 'GFPhigh' parasites (Figure 1B). Sorted 
samples were collected in 300 µl Trizol (Life Technologies). For the series of 
experiments relating to this paper we performed six blood stage infections. In two out 
of six blood stage infections, parasitemia was low (<0.2%) at the time of mosquito 
feeding. This resulted in poor sporozoite yields and not enough liver stage forms for 
FACSsort. The four other infections all resulted in successful liver stage infections 
with sufficient parasites for FACSsort, with one of the infections used for validation 
experiments. Collected ‘GFPlow’ samples contained 1,193-2,713 Hz (on average 1826 
Hz); collected ‘GFPhigh’ samples contained 921-1,245 cells (on average 1,056 Sz). 
After sorting, tubes were vortexed ± 30 sec and transferred to a -80 °C freezer for 
storage until RNA extraction. During sorting, small amounts of GFPlow, GFPdim and 
GFPhigh samples were collected in William's B to analyze the quality of the sort: 
samples were transferred to a 96 well plate and analyzed using a high-throughput high-
content imaging system (Operetta, Perkin-Elmer).  
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Neocuproine treatment 
 
Following salivary gland dissection of infected A. stephensi mosquitoes 50,000 
sporozoites were added per well to primary macaque hepatocyte cultures in 96-well 
plates as described earlier (Zeeman et al., 2014). Neocuproine (Sigma cat. 121908), 
dissolved in DMSO and subsequently diluted in William’s B medium to 10, 1, and 0.1 
µM was added in duplicate or triplicate wells to the cultures after sporozoite invasion 
and incubated with regular refreshments until fixation at day 6. Medium containing 
DMSO was used as control. Following methanol fixation immunofluorescence 
analysis was performed and parasites were counted using a high-content imaging 
system (Operetta; Perkin-Elmer) as reported previously (Zeeman et al., 2014). 
 
Protein and antibody production  
 
An E. coli codon optimized gene for PcyM_0533600 (Genscript, USA) was 
synthesized and protein (Q30-K145) was expressed in BL21 cells. The protein was 
purified using a Ni-IMAC column followed by gel-filtration/buffer exchange and used 
to immunize rats (Eurogentec, Belgium). In addition, monoclonal antibodies were 
raised against selected proteins at Genscript, USA. 
 
 
 
 84 
Immunofluorescence analysis (IFA) 
 
For IFA validation assays of hepatic stages, collagen coated Cell Carrier-96 
well plates (Perkin Elmer) or Permanox Lab-Tek chamber slides (Nunc) were seeded 
with fresh primary rhesus hepatocytes and infected with wild type P. cynomolgi M 
sporozoites following procedures as described above and previously (Zeeman et al., 
2014). For long-term culture, to enable IFA analysis of day 19 liver stage parasites, 
matrigel was placed on top of the hepatocytes as previously described (Dembélé et al., 
2014). At day 6/7 (or day 19) post sporozoite inoculation, cells were briefly fixed in 
cold methanol followed by three washes in PBS. Infected hepatocytes were blocked in 
100 mM glycine for 5 min. at room temperature. After three washes with PBS, cells 
were incubated for 1-2 h at room temperature with hybridoma supernatant (undiluted), 
polyclonal antiserum (1:100) or purified IgG (25 µg/ml) diluted in PBS. Primary 
antibodies were mouse mAb anti-H4K8ac (Active motif, #61525, 1:500 dilution), 
polyclonal rat-anti-ETRAMP (PcyM_0533600, Eurogentec), mouse mAb 1G4E7 
against GAP45 (PcyM_1442700, Genscript) and mouse mAb 5B10C7 against 
Ferredoxin (PcyM_1419800, Genscript). Anti-P. cynomolgi HSP70.1 polyclonal 
rabbit serum (Zeeman et al., 2014) was included to detect parasites. Cells were washed 
three times in PBS and incubated 1-2 h at room temperature with secondary antibodies 
diluted in PBS with DAPI. Fluorescein isothiocyanate (FITC)-labeled goat anti-rabbit 
IgG (Kirkegaard and Perry Laboratories, 1:200), FITC-labeled goat anti-mouse IgG 
(Kirkegaard and Perry Laboratories, 1:200), Alexa-594 labeled chicken anti-mouse 
IgG (Invitrogen, 1:2000), or Alexa-594 labeled chicken anti-rabbit IgG (Invitrogen, 
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1:2000) were used as secondary antibodies. Following three washes with PBS, 
mounting was performed with CITIFLUOR AF1 (Agar Scientific). Images were taken 
using a Nikon Microphot FXA fluorescence microscope equipped with a DS-5M 
digital camera or with a Leica DMI6000B inverted fluorescence microscope equipped 
with a DFC365FX camera. For IFA staining of blood stage parasites, blood smear 
preparations of P. cynomolgi infected red blood cells were fixed with methanol. 
Primary and secondary antibodies were diluted in 1% FCS/PBS and each staining was 
for 1 h at room temperature. Primary antibodies were polyclonal rat-anti-ETRAMP 
(PcyM_0533600) at 25 µg/ml and rabbit anti-Band 3 monoclonal antibody (Abcam 
ab108414, 1:100). Secondary antibodies were Alexa-594 labeled chicken anti-rabbit 
IgG (Invitrogen, 1:2000) and mouse serum adsorbed FITC-labeled goat anti-rat IgG 
(Kirkegaard and Perry Laboratories, 1:200); DAPI was included.  Slides were rinsed 
in PBS (4-5x) and mounted with CITIFLUOR AF1. Images were taken using a Leica 
DMI6000B inverted fluorescence microscope equipped with a DFC365FX camera. 
 
RNAscope in situ hybridization 
 
P. cynomolgi M infected primary rhesus hepatocytes cultured for 6 days in 
CellCarrier-96 well plates (Perkin-Elmer) were fixed for 30 min. at RT in 4% 
paraformaldehyde in PBS (Affymetrix), dehydrated and stored at -20°C until further 
processing.  RNA in situ detection was performed using the RNAscope Multiplex Kit 
(Advanced Cell Diagnostics) according to the manufacturer’s instructions. RNAscope 
probes used were: gapdh (PcyM_1250000, region 113-997) and hsp70 
 86 
(PcyM_0515400, region 606-1837). Following the RNA-FISH protocol, IFA was 
performed using rabbit anti-PcyHSP70 to stain the parasites as described above. Z-
Stack images were acquired on the Operetta system (Perkin-Elmer) using a 40x 
objective NA 0.95 and maximum projections are shown.  
 
RNA sequencing 
 
Total RNA was isolated from 5 different samples of FACS-sorted small 
parasite infected cells (GFP-low, e.g. hypnozoites) and 5 samples of FACS-sorted 
large parasite infected cells (GFP-high, e.g. liver schizonts). All samples were stored 
in TRIzol (Thermo Fisher) and total RNA extracted using the Direct-zol™ RNA 
MiniPrep Kit (Zymo Research) including on-column DNase digestion according to the 
manufacturer’s instructions. RNA amplification was performed using the 
TargetAmp™ 2-Round aRNA Amplification Kit 2.0 (Epicentre). The quality of the 
RNA samples (before and after the amplification) was assessed with the RNA 6000 
Pico and Nano kits using the Bioanalyzer 2100 instrument (Agilent Technologies). 
RNA-seq cDNA libraries were prepared from the amplified RNA samples using the 
TruSeq mRNA Sample Prep kit v2 (Illumina). The quality of the cDNA libraries was 
assessed with the Bioanalyzer 1000 DNA kit (Agilent Technologies). RNA-seq cDNA 
libraries were then sequenced in paired-end mode, 2 x 76 bp, using the Illumina 
HiSeq2500 platform. Read quality was assessed by running FastQC (version 0.10) on 
the FASTQ files. Sequencing reads showed high quality, with a mean Phred score 
higher than 30 for all base positions. Over 857 million 76-base-pair (bp) paired-end 
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reads were used for the bioinformatics analysis. Reads from each sample were aligned 
to a genomic reference composed of the combination of the malaria parasite 
Plasmodium cynomolgi M strain genome and one of the following host genomes: 
Macaca mulatta (Zimin et al., 2014) (http://www.unmc.edu/rhesusgenechip/), and 
Macaca fascicularis (http://www.ncbi.nlm.nih.gov/assembly/GCF_000364345.1/). 
Reads mapping to the parasite genome was used to quantify gene expression by using 
the Exon Quantification Pipeline (EQP) (Schuierer & Roma, 2016). On average, a 
range of 38% (minimum) to 84% (maximum) of total reads were mapped to the 
parasite and host genomes, and between 17% and 65% were aligned to the parasite 
and host exons (expressed reads). A QC inspection of the aligned sequencing reads 
showed an expected coverage bias towards the 3’ end of the transcripts that is due to 
the use of the amplification kit. Based on the alignment statistics, we decided to 
exclude two Sz samples and one Hz sample from further analyses. Genome and 
transcript alignments were used to calculate gene counts based on the P. cynomolgi M 
strain gene annotation (Pcynom M_v2, Pasini et al., 2017) provided by the BPRC and 
the Wellcome Trust Sanger Institute.  
Gene raw counts represent the total number of reads aligned to each gene. These values 
were normalized using the following four-stage approach (Figure 1-figure supplement 
3). First, gene raw counts were divided by the total number of mapped reads for each 
sample and multiplied by one million to obtain Counts Per Million (CPM) to account 
for varying library sizes (library size normalization). In a given sample, one CPM 
indicates that a specific gene was detected by one read out of one million of mapped 
reads. Second, a further normalization of the CPMs based on the BioConductor 
package DESeq2 (Love, Huber, & Anders, 2014) was performed for the samples of 
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each stage separately to account for the variation of #parasite-cells/#host-cells fraction 
within one stage (group-wise normalization). Third, an adjustment of mean expression 
ratio between schizont and hypnozoite samples was computed by using host 
expression values to further account for the difference in cell size and RNA amount 
per cell which is expected between the schizont and the hypnozoite liver forms (host 
normalization). The host normalized counts were further divided by the gene length in 
kb to obtain the Fragments Per Kilobase per Million values (FPKM) (gene length 
normalization). The host normalized gene expression values  were also used to identify 
differences in gene expression between the schizont and the hypnozoite samples using 
the BioConductor package DESeq2 (Love et al., 2014). We therefore calculated the 
list of genes that are differentially expressed between the liver schizonts and the 
hypnozoites along with the log2 fold changes and p-values after Benjamini-Hochberg 
false discovery rate (FDR) correction for multiple hypothesis testing.  
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Figure 1-figure supplement 3. Normalization of gene expression values. (A) 
Overview of the normalization process from raw counts to FPKMs. This process 
comprises four steps which are library size normalization, group-wise normalization, 
host normalization, and gene length normalization. See Methods for a description of 
each step. (B) Effect of the normalization on gene expression levels. GAPDH is shown 
as an example. (C) Comparison of normalization strategies. Left: group-wise 
normalization is used to keep the expected difference in absolute level of gene 
expression between schizonts and hypnozoites. Right: uniform normalization (as 
applied by Cubi et al.) brings the distribution of the expression values of the 
hypnozoite and schizont samples onto equal levels. 
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Orthology and pathway analysis 
 
In order to annotate the Plasmodium cynomolgi proteome, we performed an 
extensive orthology analysis that included the following proteomes in addition to P. 
cynomolgi M strain: P. falciparum 3D7, P. berghei ANKA, P. knowlesi H, P. vivax 
Sal1, P. yoelii yoelii 17X, H. sapiens, D. melanogaster, M. musculus, R. norvegicus, 
and S. cerevisiae. The Plasmodia proteomes were obtained from PlasmoDB 
(http://PlasmoDB.org/) version 26 (Aurrecoechea et al., 2009), the other proteomes 
from UniProt (release 2015_12) (Bateman et al., 2015). Our orthology analysis is 
based on the OrthoMCL methodology but implemented in-house to work with our 
local high-performance computing environment. Conceptually, this comprised the 
following steps: 1) alignment of all protein sequences against each other with blastp 
(Altschul, Gish, Miller, Myers, & Lipman, 1990); 2) calculation of the percent match 
length by determining all amino acids participating in any HSP between two proteins 
divided by the length of the shorter protein; 3) filtering out of the blast results with a 
percent match length below 50% or an E-value above 10-5; 4) determination of 
potential orthologs and paralogs and their normalized E-values; 5) clustering of the 
resulting weighted similarity graph with MCL. See Fischer 2011 et al (Fischer et al., 
2012) for more details, and Figure 6.12.1 contained within for an overview. The 
obtained groups of proteins were used to propagate protein annotations from other 
species to P. cynomolgi. Using this approach, we were able to group a total of 6,040 
P. cynomolgi proteins (86% of the total 7,030 proteins) with at least one protein from 
another species, and 2295 (33%) P. cynomolgi proteins were linked to 257 malaria 
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pathways mapped from PlasmoDB. For the identification of pathways that are 
expressed in the liver stages, we used a stringent cut-off to focus only on those genes 
whose expression is consistent across replicates (>1 FPKM in at least 2 replicates). 
This resulted into 2,748 genes and 88 pathways expressed in 2/4 Hz replicates, and 
5,323 genes and 233 pathways expressed in 2/3 Sz replicates. 
 
Pathway and Gene Ontology enrichment analyses  
 
Gene sets were collected from two sources: PlasmoDB (Aurrecoechea et al., 
2009) and Gene Ontology (Ashburner et al., 2000; The Gene Ontology Consortium, 
2017). The gene sets from PlasmoDB mostly correspond to “Metabolic pathways”, 
whereas the gene sets from the Gene Ontology correspond to general organizational 
principles of biology (such as “translation”). Many of the pathways from PlasmoDB 
are manually curated, whereas large parts of the annotations in the Gene Ontology are 
derived and propagated from one species to another by algorithms. The gene sets were 
mapped by orthology to Plasmodium cynomolgi. We employed two standard 
approaches to determine the relevance of gene sets with respect to our RNAseq data: 
1) overrepresentation analysis via a hypergeometric test; and 2) Kolmogorov-Smirnov 
test, as proposed in the original GSEA publication (Subramanian et al., 2005). The 
main differences between the two approaches is that the first one requires a 
predetermined criterion to select genes of interest in which overrepresented 
annotations are to be determined; the second does not need any such cut-off, as the test 
statistic is based on a ranking of all genes in the experiment. 
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For the enrichment analyses, we applied several criteria of increasing stringency to 
select stage-specific genes of interest from our RNA-seq experiment: 
• All genes within a certain stage that are expressed with at least 1 FPKM in at 
least 2 samples in that stage (e.g. Hz or Sz). 
• All genes within a certain stage that are expressed with at least P25 FPKM in at 
least 2 samples in that stage, where P25 is the 25th percentile (1st quartile) of the 
expression of the pooled samples of that stage (e.g._Hz_q1 or Sz_q1). 
• All genes within a certain stage that are expressed with at least P75 FPKM in at 
least 2 samples in that stage, where P75 is the 75th percentile (3rd quartile) of 
the expression of the pooled samples of that stage (e.g. Hz_q3 or Sz_q3); 
• All genes that satisfy criterion 2 in a stage but in no other stage (e.g. 
Hz_q1_specific or Sz_q1_specific). 
• All genes that satisfy criterion 3 in a stage but in no other stage (e.g. 
Hz_q3_specific or Sz_q3_specific). 
Genes satisfying the criteria above were determined for all stages and used as input for 
an overrepresentation analysis.  
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Targeted amplification and sequencing of the etramp gene 
 
Blood stage, sporozoite, schizont and hypnozoite RNA samples were reverse 
transcribed using the High Capacity RNA-to-cDNA Kit (#4368814, Thermo 
Scientific). The etramp gene (PcyM_0533600) was amplified in all the samples using 
the Phusion DNA Polymerase kit (#F530, Thermo Scientific) with the following 
primers: ACTCCTTGGTGGTGCCTTAG (FWD); TGCGGGGCCCTTATCTTT 
(REV). The Ovation Low complexity Sequencing System kit (#9092-256, NuGEN) 
was used to prepare the sequencing libraries. Libraries were multiplexed and 
sequenced in paired-end mode, at a read length of 2 × 300 bp, using the MiSeq platform 
(Illumina). The resulting FASTQ files were demultiplexed and aligned against the P. 
cynomolgi M strain genome (Pcynom M_v2, unpublished) using STAR version 2.5.2a 
(Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S & Chaisson M, 2013) 
for the detection of the amplified regions. The Integrative Genomics Viewer (IGV) 
(James T. Robinson, Helga Thorvaldsdóttir, Wendy Winckler, Mitchell Guttman, Eric 
S. Lander, Gad Getz, 2011) version 2.3.75 was used to visualize the aligned reads in 
the genome context. The etramp gene view presented in Figure 2D was generated using 
the R/Bioconductor GViz package (Hahne & Ivanek, 2016). 
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Comparison with published data  
 
Published expression data of P. cynomolgi liver stages (Cubi et al., 2017) were 
downloaded from the EMBL-EBI European Nucleotide Archive [ENA: PRJEB18141; 
Sample group: ERS1461774] and compared to our RNA-seq data. It was not possible 
to compare the gene lists from Cubi et al. directly with the genes from this manuscript 
because the two studies used different P. cynolmolgi reference genomes and gene 
annotation files. The downloaded Fastq files of Cubi et al. were thus processed with 
the genome reference and annotation files from (Pasini et al., 2017), the same RNA-
seq analysis pipeline, and the same normalization method as was used for our data set 
and which is described in the ‘RNA sequencing’ paragraph above. The correlation 
plots were generated on log10 normalized CPMs after the addition of a pseudo-count 
of 0.1. The Venn diagram plots were generated on genes expressed above the cut-off 
of 1 FPKM in the hypnozoite and schizont samples, and drawn using the on line tool 
available at the following website: 
http://bioinformatics.psb.ugent.be/webtools/Venn/.  
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Results  
 
Hypnozoites express a smaller set of genes than schizonts 
 
Six to seven days after P. cynomolgi sporozoite infection of primary simian 
hepatocytes, we FACS-purified hepatocytes containing hypnozoites and liver 
schizonts and prepared RNA for high-throughput sequencing (Figure 1). After quality 
control, we excluded 3 samples due to their low number of parasite reads, resulting in 
a dataset containing 3 independent schizont samples and 4 independent hypnozoite 
samples for analyses. To quantify parasite-specific expression for each P. cynomolgi 
gene, we determined the number of sequencing reads aligned to genes and computed 
gene expression values as the number of Fragments Per Kilobase per Million 
fragments mapped (FPKM) (Schuierer & Roma, 2016). Overall, the raw gene 
expression values of the schizont samples are ~14-fold higher than those of the 
hypnozoite samples (p-value 1.1e-3). This global difference in gene expression 
between multi-nucleated schizonts and uni-nuclear hypnozoites could be partly 
attributed to differences in the number of parasite transcriptionally active units per 
hepatocyte, however it is not possible to determine this exact number. In order to 
account for this difference, we normalized the gene expression values against the total 
number of host reads per sample which we posit to represent a constant host RNA 
content across all samples (see Methods). All data reported in Figures 1 to 4 show 
FPKM values after such normalization. A threshold of FPKM greater than 1 is deemed 
equivalent to one transcript copy per cell (Mortazavi, Williams, Mccue, Schaeffer, & 
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Wold, 2008). Using this threshold, hypnozoites generally express a lower number of 
genes compared to schizonts (respectively, 3,308 vs 5,702 genes at average FPKM per 
group ≥1). In addition, the expression level of these genes in schizonts is higher than 
in hypnozoites (average expression 89.14 and 9.88 FPKM, respectively) (Figure 1C). 
To further validate this finding we carried out RNA fluorescence in situ hybridization 
(RNA-FISH) to quantitatively evaluate the expression of abundantly expressed genes 
at the single-cell level in liver stage cultures. In agreement with the RNA-Seq results, 
the RNA-FISH staining with probes for gapdh and hsp70 showed a markedly lower 
level in hypnozoites compared to schizonts’ expression (Figure 1D). We then 
compared the gene expression data with those recently published by Cubi et al. (Cubi 
et al., 2017). Since the two studies used different reference genomes and annotation 
files, we reprocessed the raw sequencing files using the P. cynomolgi genome from 
Pasini et al. (Pasini et al., 2017) and the data analysis methods that we used in this 
manuscript. The schizonts data from Cubi et al. showed a high correlation of 0.95 and 
a large consensus between the two replicates, which compared with a slightly lower 
but equally high correlation (average correlation 0.88) and high overlap between the 
triplicates profiled in this study (Figure 1-figure supplement 1). In stark contrast, while 
gene expression data reported here showed a high concordance between the four 
biological replicates of hypnozoites (average correlation 0.68) and a large overlap of 
2,804 out of 4,198 genes expressed in at least two samples (Figure 1-figure supplement 
1), the data from Cubi et al. showed a lower correlation for the two hypnozoite samples 
(correlation of 0.38; Figure 1-figure supplement 1) and a scarse consensus between the 
two replicates (204 out of 1,147 genes; Figure 1-figure supplement 1). Of these 204 
genes, 175 overlap with at least one of our hypnozoite samples (Figure 1-figure 
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supplement 1), and can thus be considered true hypnozoite transcripts. Compared to 
the here reported 2,804 hypnozoite transcripts, this indicates that many genes and 
pathways expressed in hypnozoites were not captured in the previous study (Cubi et 
al., 2017). 
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Figure 1. Transcriptomics of relapsing malaria liver stage parasites. (A) Scheme of experimental 
approach for purification and RNA-sequencing of cultured P. cynomolgi M malaria liver stage schizonts 
(Sz) and hypnozoites (Hz). To enable FACS purification, P. cynomolgi parasites that stably express 
GFP using a Plasmodium Artificial Chromosome (PAC) were used. For further details, see methods. 
(B) Gating strategy included an extra gate, 'GFPdim', not used in subsequent RNA-seq analysis to ensure 
a strict separation of 'GFPlow' and 'GFPhigh' parasites. (C) Distribution of average gene expression 
values in the hypnozoite (green; n=4) and schizont (blue; n=3) samples. FPKM, Fragments per kilobase 
of transcript per million mapped reads. (D) Top panel showing RNA fluorescence in situ hybridization 
(RNA-FISH) of day 6 P. cynomolgi Sz and Hz with probes against gapdh (PcyM_1250000) and hsp70 
(PcyM_0515400). Scale bars, 20 µm. Lower panel shows gene expression values (FPKM) for gapdh 
and hsp70 of individual Hz and Sz samples as determined by RNA-sequencing	
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Figure 1-figure supplement 1. Comparison with published data. (A) Scatter plot showing all 
pairwise log10 normalized CPM correlations between samples from Cubi et al. The upper right part of 
the panel shows the value of the calculated Pearson correlation coefficients. The Venn diagrams show 
the overlap of genes expressed above 1 FPKM in the hypnozoite samples and in the schizont samples, 
respectively. (B) Same as A, but showing data from this study. (C) Venn diagrams showing the overlap 
of genes expressed above 1 FPKM in the three schizont samples from this study and the 5,502 genes 
shared by the two schizont samples from Cubi et al. (Sz-Cubi). (D) Venn diagrams showing the overlap 
of genes expressed above 1 FPKM in the four hypnozoite samples from this study and the 204 genes 
shared by the two hypnozoite samples from Cubi et al. (Hz-Cubi). 
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Although the transcription level in hypnozoites appears to be generally reduced, we 
found evidence that there is ongoing active transcription in hypnozoites, up to day 7, 
as demonstrated by the positive staining with antibodies recognizing the acetylated 
H4K8 protein, a marker of open chromatin (Gupta et al., 2013) (Figure 1-figure 
supplement 2). Thus, when compared to proliferating liver schizonts, “dormant” 
hypnozoites express only less than half of the parasite genome and the rate of 
transcription of individual genes also appears to be very low.  
 
 
 
Figure 1-figure supplement 2.  IFA staining of acetylated H4K8 in P. cynomolgi liver stages. 
Immunofluorescence analysis of day 7 P. cynomolgi liver stage schizont (upper panel) and two 
hypnozoites (lower panel). Scale bar 25 µm. 
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Comparative transcriptomic analysis allows the 
identification of differential markers of P. cynomolgi liver 
stages  
 
We further explored the liver stage transcriptomes to identify those genes with 
significantly different expression levels between hypnozoites and schizonts (>2 fold-
change absolute value, 10% false discovery rate (FDR)) (Figures 2A and 2B). Our 
results indicate that the expression of only a dozen genes might be enhanced in 
quiescent hypnozoites as compared to growing liver schizonts, while the expression of 
thousands of genes is significantly lower in hypnozoites than in schizonts. To 
determine whether protein expression follows the RNA differential expression 
observed, we selected a few genes that were upregulated in either stage and raised 
antibodies against recombinant predicted proteins. Using these antibodies, we then 
performed immunofluorescence analysis (IFA) on cultured liver stages. Unexpectedly, 
antibodies against PcyM_0533600 (ETRAMP, amino acids Q30-K145), one of the 
most up-regulated genes in the hypnozoite samples, failed to detect the protein in day 
6 P. cynomolgi liver stage parasites. The same antibodies strongly reacted with P. 
cynomolgi blood parasites (Figure 2C) but failed to detect the protein in sporozoites 
(data not shown). Sequence analysis of RT-PCR products from different parasite 
stages revealed that only blood stage parasites express the predicted full-length 
PcyM_0533600 mRNA, while alternatively spliced transcripts (including premature 
stop codons) were found in sporozoite, schizont, and hypnozoite samples (Figure 2D), 
explaining our inability to detect the predicted protein in these stages.  
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Figure 2. Relapsing malaria liver stages display low transcription levels and differ from 
developing stages. (A) Volcano plot showing genes differentially expressed in hypnozoites (Hz, n =4 
biological replicates) versus schizonts (Sz, n=3 biological replicates). The y-axis represents the 
significance as –log10 FDR-adjusted p-values and the x-axis represents the expression changes as log2 
fold-change of Hz and Sz. Genes used for validation are marked. (B) Gene expression values (FPKM) 
of individual Hz and Sz samples from genes selected for validation. (C) Immunofluorescent staining of 
ETRAMP protein (green), DAPI (blue) and red blood cell (red) in P. cynomolgi blood stage parasites. 
Scale bars 25 µm. (D) Genome browser view of the etramp gene (PcyM_0533600) showing intron 
splicing events detected by sequencing of RT-PCR products in Blood stages, Sporozoites (SPZ), 
Schizonts (Sz) and Hypnozoites (Hz). Retained intron events are highlighted in blue; asterisk shows 
premature termination codons (PMTs). The predicted protein (Pred. Protein), the recombinant portion 
of the protein (Rec. Protein) used for antibody production (amino acids Q30-K145), and the positions 
of the primers used to generate the RT-PCR products are shown. (E) Immunofluorescent staining 
patterns of Ferredoxin (PcyM_1419800), GAP45 (PcyM_1442700), and HSP70 (PcyM_0515400) in 
day 6 P. cynomolgi liver schizonts and hypnozoites. Arrows, hypnozoites. Lower panel shows 
magnified image of GAP45 stained hypnozoite.  
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To further validate our dataset, antibodies were raised against three other proteins, 
PcyM_0515400 (HSP70), PcyM_1419800 (Ferredoxin) (Miotto et al., 2015) and 
PcyM_1442700 (Glideosome Associated Protein GAP45). These antibodies did react 
with P. cynomolgi day 6 liver stage parasites showing staining of liver schizonts 
(Ferredoxin), primarily hypnozoites (GAP45) or both schizonts and hypnozoites 
(HSP70), mirroring precisely the RNA-seq data for these genes (Figure 2E). 
Antibodies against GAP45, an inner membrane complex (IMC) marker (Kono et al., 
2012) and a member of the glideosome motor complex (Harding & Meissner, 2014), 
stained the periphery of 6-days old hypnozoites (Figure 2E middle and lower panels). 
In contrast, the staining pattern in schizonts was weaker and sparsely distributed (early 
schizonts) or absent (large mature schizonts) (Figure 2E middle panel). These data 
concur with previous reports describing the progressive loss of the IMC during 
conversion of the motile sporozoite into a replication-competent metabolically active 
liver stage form (Jayabalasingham, Bano, & Coppens, 2010). Interestingly, we could 
still detect GAP45 in hypnozoites at day 19 (Figure 2-figure supplement 1). The long-
term presence of GAP45 may be due to low protein turnover in hypnozoites or a 
functional requirement of this protein for hypnozoite maintenance. Taken together the 
RNA-FISH and immunofluorescence experiments confirmed the general trends we 
observed in the RNA-seq dataset and we anticipate that further mining of this gene list 
will yield differential markers of schizont development and hypnozoite maintenance. 
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Figure 2-figure supplement 1. GAP45 protein expression in day 19 hypnozoite. Staining of GAP45 
protein (PcyM_1442700) in a 19-day P. cynomolgi hypnozoite parasite by immunofluorescence 
analysis (IFA). Scale bar 25 μm. 
 
 
Hypnozoites express few core pathways including the 
physiological hallmarks of dormancy 
 
To investigate the physiology of P. cynomolgi liver stages, we performed a 
pathway analysis in schizonts and hypnozoites. Through orthology mapping, P. 
cynomolgi genes were assigned to 257 Plasmodium falciparum pathways 
(Aurrecoechea et al., 2009). Gene ontology and pathway enrichment analyses 
highlighted that hypnozoites express genes related to translation, RNA processing and 
epigenetic processes (e.g. histone acetylation and methylation). These pathways and 
processes were also enriched in the schizonts, which however expressed more 
processes related to the cell nucleus, hinting at the differences in transcriptional 
activity. Schizonts clearly express a much higher number of pathways than 
hypnozoites (Figure 3A). Of all the pathways included in this analysis, only ~34% (88 
out of 257 pathways) express more than half of their constituent genes above the 
threshold of 1 FPKM in the hypnozoite while the equivalent is true for ~91% (233 out 
of 257) of the pathways in schizonts. In the schizonts, energy and glucose metabolism 
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pathways, such as pentose phosphate cycle enzymes, CoA biosynthesis pathways and 
mannose/fructose metabolism are all highly expressed with nearly all genes in those 
pathways detected above 1 FPKM (Figure 3A). In contrast, those pathways are nearly 
absent in the hypnozoite, which is consistent with the quiescence and low metabolism 
that may be expected in dormant forms.  
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Figure 3. Pathway analysis of the malaria liver stages reveals the core biological functions 
required for hypnozoites maintenance. (A) Heat map showing expression of Plasmodium pathways 
in schizonts and hypnozoites. A total of 257 pathways annotated in P. falciparum were assigned to P. 
cynomolgi through orthology (see methods). Pathways where the fraction of genes detected above the 
threshold of FPKM of 1 is 100% are shown in red, between 50% and 100% in grey, between 0% and 
50% in blue. (B) Same as a) but showing only erythrocytic invasion and schizont specific pathways. 
(C) Same as a) but showing house-keeping pathways. 
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Interestingly, some but not all erythrocytic invasion pathways are expressed only in 
schizonts, suggesting that already at day 6 the parasites express some of the genes 
required for merozoite function and red blood cell invasion (Figure 3B). Hypnozoites 
mostly express core housekeeping pathways such as those involved with nucleus and 
chromatin maintenance, transcription, translation and mitochondrial respiration, but 
no DNA replication enzymes (Figure 3C, Figure 3-figure supplement 1). Notably, 
genes known to be required for ATP homeostasis in non-replicating dormant 
Mycobacterium tuberculosis (Rao et al., 2008), such as various components of the F0-
F1 ATPase complex, are similarly significantly expressed in hypnozoites (Figure 3-
figure supplement 1). Collectively, our analyses reveal that hypnozoites express 
pathways previously associated with quiescence and required for the maintenance of 
chromosome integrity and ATP homeostasis. 
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Figure 3-figure supplement 1. Liver stage schizont (Sz) and hypnozoite (Hz) gene expression 
values (FPKM) for pathways associated with quiescence. (A) Pathways involved in maintenance of 
membrane potential and ATP biosynthesis. (B) Pathways involved in preservation of genome integrity. 
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Expression pattern of potential drug targets in P. cynomolgi 
liver stages  
 
In the liver schizonts and hypnozoites transcriptomic dataset, we looked at the 
expression FPKM values for clinically and chemically validated drug targets (reported 
in Figure 4A). While all drug targets are expressed in the schizonts above the threshold 
level of 1 FPKM, only a few of them are detectable above this level in the hypnozoites. 
For example, we could not detect PI4K transcripts in day 6 hypnozoites while this gene 
is abundantly expressed in schizonts (Figure 4A), which is consistent with previously 
published data on Plasmodium PI4K inhibitors having prophylactic but not radical 
curative activity in the P. cynomolgi model (Zeeman et al., 2016). In contrast, the 
antifolate drug target DHFR is detectable above 1 FPKM in hypnozoites, yet 
antifolates do not exhibit radical cure in the P. cynomolgi model (Schmidt, Fradkin, 
Genther, Rossan, & Squires, 1982). Likewise, DHODH, the target of the clinical 
candidate DSM265, is detectable in hypnozoites while this compound shows poor 
activity against hypnozoites in vitro (Phillips et al., 2015). Although the P. cynomolgi 
ATP4 ortholog, the clinically validated target of KAE609, is detectable in schizonts at 
low level, it is not critical as PfATP4 inhibitors are not active in liver stages (Jiménez-
díaz et al., 2014; Rottmann et al., 2010; Vaidya et al., 2014). Thus, it appears that 
function could not be directly inferred from the liver stages expression data.  
Plasmodium parasite survival and replication depends on the import of nutrients and 
solutes from its host cell and some transporters have been proposed to be tractable 
drug targets for malaria (Hapuarachchi et al., 2017; Pain et al., 2016; Slavic, Krishna, 
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Derbyshire, & Staines, 2011; Weiner & Kooij, 2016). Consistently, we observe high 
FPKM values for a broad range of transporters in both liver schizonts (35 putative 
transporters with FPKM values >10) and hypnozoites (7 transporters with FPKM 
values >10 and 25 transporters with FPKM values >1. Heavy metal homeostasis has 
been shown to be critical to liver stage (Kenthirapalan, Waters, Matuschewski, & 
Kooij, 2016; Sahu et al., 2014; Stahel et al., 1988) development and consistently we 
found several heavy metal transporters to be expressed in all liver stages (Figure 4B). 
Remarkably, two putative copper transporters (PcyM_1331900 and PcyM_1277100) 
showed high FPKM values for both liver stage schizonts and hypnozoites (Figure 4B), 
suggesting a role for copper homeostasis in liver stage development and quiescence. 
To determine whether copper was critical to P. cynomolgi liver stages, we treated 
infected hepatocytes with a copper chelator, neocuproine (Choveaux, Przyborski, & 
Goldring, 2012; Kenthirapalan, Waters, Matuschewski, & Kooij, 2014). Neocuproine 
treatment, initiated 1-2 hours after infection with sporozoites and continued for 6 days, 
indeed showed pronounced cidal effects on the viability of both liver schizonts and 
hypnozoites (Figure 4C) at the highest concentration tested. In one of the three assays 
we noted a limited effect on hepatocyte viability at this concentration, as concluded 
from from hepatocyte nuclei counts in the analysis. These data provide some 
preliminary chemical validation of the hypothesis that copper homeostasis may be 
critical for schizonts replication and hypnozoites survival. 
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Figure 4. Expression of potential malaria drug targets in hypnozoites. (A) Table showing the list of 
known malaria drug targets along their expression levels in the liver stages and the targeting compound. 
(B) Table showing list of putative heavy metal transporters with chelating agents and their expression 
levels in the P. cynomolgi liver stages. (C) Structure formula of the copper chelator neocuproine. Dose-
dependent effect of day 0-6 neocuproine treatment on P. cynomolgi liver stage schizonts (Sz) and 
hypnozoites (Hz). Bar charts show averaged results of 3 independent assays (7 wells per compound 
dilution in total) with standard error of the mean (sem). 
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Discussion  
 
Because malaria liver stage parasites are more difficult to culture in vitro, the 
parasite hepatic life cycle has been neglected and our collective knowledge of those 
stages remains sparse. The need for new pre-erythrocytic vaccination strategies 
(Longley, Hill, & Spencer, 2015) and novel drug therapies to combat relapsing malaria 
parasites (Campo et al., 2015), recently fueled much interest for further investigations 
of the biology of liver stage parasites. As a significant contribution to these efforts, we 
report here a comprehensive comparative transcriptomics dataset of both developing 
and dormant liver stage P. cynomolgi malaria parasites. Using this dataset, we 
identified two protein markers that differentiate quiescent from actively dividing 
parasites and demonstrate that copper homeostasis is critically required for P. 
cynomolgi parasites replication and survival in hepatocytes. It is our hope that through 
multi-disciplinary collaborative efforts the research community will further mine this 
dataset to gain further insights in the biology of Plasmodium dormancy. 
Recently a first P. cynomolgi hypnozoite transcriptomic dataset has been published 
(Cubi et al., 2017) which reports about 120 differentially expressed genes of which 69 
are more than 3-fold upregulated, while we report here a much smaller number of 
upregulated genes in hypnozoites. It is important to note that Cubi et al. applied a 
uniform normalization that assumes that signals from different samples should be 
scaled to have the same median or average value thus not taking into account the size 
differences of replicating and dormant liver stages (Mikolajczak et al., 2015). This 
could have potentially biased their comparative analysis towards an over-estimation 
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of the gene expression levels in hypnozoites. In contrast, we applied a group-wise 
normalization to the expression data in order to keep the expected difference in 
absolute level of gene expression between schizont and hypnozoite (Figure 1-figure 
supplement 3). Cubi et al. proposed that the gene PCYB_102390 (PcyM_1014300 in 
our dataset) encodes an ApiAP2 transcription factor AP2-Q (for quiescence) which 
could act as a master regulator of the hypnozoite fate (Cubi et al., 2017). However 
even after normalization, we failed to detect expression of this gene in 4 hypnozoite 
samples (Figure 3-figure supplement 2). Notwithstanding we detected transcripts for 
9 other Api-AP2 genes in hypnozoites (Figure 3-figure supplement 2). None of the 
AP-AP2 genes, including PcyM_1014300, are, however, exclusive for relapsing 
malarias, as suggested previously (Cubi et al., 2017). Only further functional 
characterization, like the studies that revealed the role of the AP2-G and AP2-G2 genes 
in gametocyte commitment (Sinha et al., 2014), will reveal the possible role of these 
AP2 transcription factors in hypnozoite identity and survival.  
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Figure 3-figure supplement 2. Expression of transcription factors in hypnozoites. (A) Heat map 
illustrating the expression values of genes belonging to putative target classes such as ZnF’s and AP2-
transcription factors. (B) Venn diagrams showing ZnF and AP2 transcription factors expressed in 
schizonts (Sz), hypnozoites (Hz), and both. 
 
 
We have previously shown that hypnozoite physiology evolves over time and while 
PI4 kinase (PI4K) inhibitors are protective when administered shortly after the initial 
malaria liver infection, they fail to radically cure monkeys when administered several 
days after parasite inoculation (Zeeman et al., 2016). In agreement with our previous 
reports, we found that at least as early as day 6 post-infection, the P. cynomolgi PI4K 
gene is not expressed in hypnozoites. The current in vitro liver stage drug assays 
cannot distinguish compounds only active against developing hypnozoites from those 
with activity against established hypnozoites (Zeeman et al., 2016). The identification 
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of markers specific to established hypnozoites would inform the design of parasites 
with transgenic reporter genes that would greatly assist the development of in vitro 
drug screening platforms (Campo et al., 2015). We found few upregulated genes in 
hypnozoites and unfortunately the most highly differentially expressed gene, 
PcyM_0533600, a member of the etramp family, was not translated in hypnozoites 
and sporozoites. The presence of such unproductive alternatively spliced transcripts in 
Plasmodium is not uncommon (Sorber, Dimon, & Derisi, 2011) and translational 
repression, including that of a member of the etramp family, UIS4 (Silvie, Briquet, 
Müller, Manzoni, & Matuschewski, 2014), has been shown to be involved in 
transitions between developmental stages of the life cycle (Lasonder et al., 2016). We 
showed nonetheless that the comparative transcriptomic dataset from this work can 
help select suitable proteins to produce monoclonal antibodies that differentially label 
specific liver stages. Further experiments are ongoing to expand the malaria liver stage 
research toolbox with selective and specific antibodies for replicating and quiescent 
liver stages. 
Dormancy is a physiological response which is relevant to various chronic human 
infectious diseases and shared by a wide range of pathogens expressing physiological 
hallmarks characteristic of microbial quiescence. Our dataset suggests that several of 
these hallmarks are present in the Plasmodium hypnozoite—namely the maintenance 
of membrane potential, ATP biosynthesis and preservation of genome integrity 
(Rittershaus et al., 2013). Indeed, pathways analysis reveals that most mitochondrial 
electron flow genes and ATP production enzymes are robustly expressed in 
hypnozoites (Figure 3-figure supplement 1). Similarly, nucleus and chromatin 
maintenance genes are highly expressed in hypnozoites, and while canonical non-
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homologous end joining (NHEJ) DNA-repair pathways are not present in Plasmodium 
(Gardner et al., 2002), we detected most of the homologous recombination repair (HR) 
enzymes as well as genes required for the maintenance of epigenetics marks (Figure 
3-figure supplement 1). In addition, the transcriptomics data together with the FISH 
validation experiments, suggest that hypnozoites display a significant reduction in 
transcriptional rate both qualitatively and quantitatively which is another hallmark of 
quiescence (Figures 1C and 1D). All of these physiological hallmarks do theoretically 
provide proven therapeutic approaches for killing quiescent organisms with the 
targeting of pathogens’ RNA polymerase(s) (Sala et al., 2010), proton-motive force 
enzymes (Andries et al., 2005) and DNA repair or epigenetic regulators (Dembélé et 
al., 2014; Sala et al., 2010). Establishing selective inhibition of these essential 
physiological processes in the parasite without significant toxicity to the host cells will 
be the key challenge for such approaches to be successful.  
In order to survive, malaria parasites utilize membrane transport proteins that allow 
the uptake of nutrients, disposal of waste products and maintenance of ion homeostasis 
(Weiner & Kooij, 2016). While some of these transporters have been implicated in 
drug resistance, recent experimental work has also supported their potential as anti-
malarial drug targets (Weiner & Kooij, 2016). Recent evidence has emerged for 
important roles of heavy metal homeostasis in sporozoite transmission and liver-stage 
development (Kenthirapalan et al., 2016; Sahu et al., 2014; Slavic et al., 2016; Stahel 
et al., 1988). Iron-deprivation inhibits liver stage growth (Goma, Renia, Miltgen, & 
Mazier, 1995; Stahel et al., 1988) and inactivation of a zinc-iron permease (ZIPCO) 
was shown to be detrimental for liver stage development (Sahu et al., 2014). We report 
here that P. cynomolgi liver stage parasites express transporters for heavy-metals, 
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including copper that in these preliminary experiments seems to be crucially needed 
for liver stages. Targeting such essential import pathways will again require selective 
inhibition of the parasite transporters for such approaches to be viable therapeutically.  
Taken together the RNA-seq data indicate that drug target liver stage expression is 
necessary but clearly not sufficient for an inhibitor to show anti-parasitic liver stage 
activity. Nonetheless, it is worth noting that the 1-deoxy-D-xylulose 5-phosphate 
reductoisomerase (DXR), the target of Fosmidomycin (Umeda et al., 2011), and the 
Elongation Factor 2 (eEF2), the target of the recently discovered drug candidate 
DDD107498 (Baragana et al., 2015), are both expressed in the hypnozoite at day 6. 
This may warrant further investigations of the potential of these compounds for vivax 
malaria radical cure. Although we did not identify pathways or drug targets specific to 
hypnozoites, our data collectively show that the hypnozoite expresses a core set of 
genes required for its basic cellular function. Identifying those essential functions that 
could be safely targeted with small molecule inhibitors should reveal the Achilles’ heel 
of the elusive hypnozoite. 
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Chapter IV 
Genomic analysis revealed new oncogenic signatures in 
TP53-mutant hepatocellular carcinoma 
 
Abstract  
 
The TP53 gene is the most commonly mutated gene in human cancers and 
mutations in TP53 have been shown to have either gain-of-function or loss-of-function 
effects. Using the data generated by The Cancer Genome Atlas, we sought to define 
the spectrum of TP53 mutations in hepatocellular carcinomas (HCCs) and their 
association with clinicopathologic features, and to determine the oncogenic and 
mutational signatures in TP53-mutant HCCs. Compared to other cancer types, HCCs 
harbored distinctive mutation hotspots at V157 and R249, whereas common mutation 
hotspots in other cancer types, R175 and R273, were extremely rare in HCCs. In terms 
of clinicopathologic features, in addition to the associations with chronic viral 
infection and high Edmondson grade, we found that TP53 somatic mutations were less 
frequent in HCCs with cholestasis or tumor infiltrating lymphocytes, but were more 
frequent in HCCs displaying necrotic areas. An analysis of the oncogenic signatures 
based on the genetic alterations found in genes recurrently altered in HCCs identified 
four distinct TP53-mutant subsets, three of which were defined 
by CTNNB1 mutations, 1q amplifications or 8q24 amplifications, respectively, that 
co-occurred with TP53 mutations. We also found that mutational signature 12, a liver 
cancer-specific signature characterized by T>C substitutions, was prevalent in HCCs 
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with wild-type TP53 or with missense TP53 mutations, but not in HCCs with 
deleterious TP53 mutations. Finally, whereas patients with HCCs harboring 
deleterious TP53mutations had worse overall and disease-free survival than patients 
with TP53-wild-type HCCs, patients with HCCs harboring missense TP53 mutations 
did not have worse prognosis. In conclusion, our results highlight the importance to 
consider the genetic heterogeneity among TP53-mutant HCCs in studies of biomarkers 
and molecular characterization of HCCs. 
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Introduction 
 
Hepatocellular carcinomas (HCCs) display extensive histologic, 
transcriptomic and genetic diversity (Lee et al., 2004; Boyault et al., 2007; Chiang et 
al., 2008; Hoshida et al., 2009; Fujimoto et al., 2012; Guichard et al., 2012; Ahn et al., 
2014; Schulze et al., 2015; The Cancer Genome Atlas Research Network, 2017). On 
the genetic level, genes involved in liver metabolism, Wnt and p53 signaling have been 
shown to be recurrently altered (Fujimoto et al., 2012; Guichard et al., 2012; Ahn et 
al., 2014; Schulze et al., 2015; The Cancer Genome Atlas Research Network, 2017). 
The most frequently mutated protein-coding genes are CTNNB1 (encoding β-catenin) 
and TP53 (encoding p53), both mutated in 20–40% of HCCs (Fujimoto et al., 2012; 
Guichard et al., 2012; Ahn et al., 2014; Schulze et al., 2015; The Cancer Genome Atlas 
Research Network, 2017). 
TP53 is the most frequently mutated gene in human cancers (Kandoth et al., 2013). 
The p53 protein modulates multiple cellular functions, including transcription, DNA 
synthesis and repair, cell cycle arrest, senescence and apoptosis (Vogelstein et al., 
2000). Mutations in TP53 can abrogate these functions, leading to genetic instability 
and progression to cancer (Vogelstein et al., 2000). Across 12 major cancer types 
(excluding HCC), 42% of cancers harbored TP53 somatic mutations, with at least 20% 
mutational rate in 10/12 cancer types and TP53 mutations are associated with inferior 
prognosis and unfavorable clinicopathologic parameters, such as tumor stage 
(Kandoth et al., 2013). Furthermore, TP53-mutant tumors are highly enriched among 
tumors driven by copy number alterations (CNAs), with most remaining TP53-mutant 
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tumors associated with the presence of somatic mutations in the Wnt and/or the RAS-
RAF-ERK signaling pathways (Ciriello et al., 2013). 
The pattern of TP53 mutations is reminiscent of both an oncogene and a tumor 
suppressor gene (Vogelstein et al., 2013). The majority (86%) of TP53 mutations are 
in the DNA-binding domain (Olivier et al., 2010; Kandoth et al., 2013). Most 
mutations in the DNA-binding domain are missense (88%) and approximately 1/3 of 
missense mutations affect the hotspot residues R175, G245, R248, R249, R273, and 
R282 (Olivier et al., 2010). Outside the DNA-binding domain, most mutations (∼60%) 
are nonsense or frameshift (Olivier et al., 2010). Mutant p53 proteins may lose the 
tumor suppressive functions and exert dominant-negative activities, but may also gain 
new oncogenic properties (Olivier et al., 2010; Muller and Vousden, 2014). Indeed, on 
the immunohistochemical level, p53 is generally detectable to various extents in 
samples with missense mutations but is undetectable in samples with truncating or 
frameshift mutations (Hall and McCluggage, 2006; Soussi et al., 2014). 
In HCC, TP53 mutational frequency has been reported to range between 22 and 33% 
(Fujimoto et al., 2012; Guichard et al., 2012; Cleary et al., 2013; Kan et al., 2013; Ahn 
et al., 2014; Jhunjhunwala et al., 2014; Shiraishi et al., 2014; Totoki et al., 2014; 
Weinhold et al., 2014; Schulze et al., 2015; Fujimoto et al., 2016; The Cancer Genome 
Atlas Research Network, 2017). However, the frequency varies between geographic 
regions, etiological factors and carcinogen exposure, with more frequent TP53 
mutations in regions where hepatitis B virus (HBV) infection is endemic (Fujimoto et 
al., 2012; Guichard et al., 2012; The Cancer Genome Atlas Research Network, 2017). 
Similar to other cancer types, TP53-mutant HCCs have been associated with features 
linked to poor prognosis, including high levels of alpha-fetoprotein, high Edmondson 
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grade, expression of stem-like markers, and activation of pro-oncogenic signaling 
pathways (Kiani et al., 2002; Breuhahn et al., 2004; Lee et al., 2004; Peng et al., 2004; 
Boyault et al., 2007; Chiang et al., 2008; Hoshida et al., 2009; Goossens et al., 2015). 
Furthermore, patients with TP53-mutant HCCs tend to have shorter overall (OS) and 
disease-free survival (DFS) (Yano et al., 2007; Woo et al., 2011; Cleary et al., 2013). 
However, it appears that not all TP53 mutations in HCCs are equal. For instance, one 
of the most common mutation hotspots affecting residues R248/249 has an overall 
frequency of ∼10% among TP53-mutant HCCs (Fujimoto et al., 2012, 2016; Ahn et 
al., 2014; Schulze et al., 2015; The Cancer Genome Atlas Research Network, 2017). 
In particular, the R249S mutation resulting from G>T transversion has specifically 
been linked to the combined effect of aflatoxin B1 exposure and HBV infection 
(Bressac et al., 1991; Hsu et al., 1991) and this mutation is detected in >75% of HCC 
from areas with high aflatoxin B1 exposure (Gouas et al., 2009; Kew, 2010). Further 
hotspot mutations affecting preferentially HCC are located at the residues V157 and 
H193 (both at ∼2%) (Fujimoto et al., 2012, 2016; Ahn et al., 2014; Schulze et al., 
2015; The Cancer Genome Atlas Research Network, 2017). Both R249S and V157F 
have been associated with stem cell-like traits and poor prognosis in HCC patients 
(Villanueva and Hoshida, 2011; Woo et al., 2011). 
Finally, molecular classification studies have invariably grouped TP53-mutant HCCs 
under the umbrella of the aggressive subclass, but it is also clear that this subclass is 
molecularly, biologically and clinically heterogeneous (Boyault et al., 2007; Hoshida 
et al., 2009; Goossens et al., 2015). 
Given the diverse pattern of TP53 mutations, taking advantage of The Cancer Genome 
Atlas (TCGA) dataset, in this study we sought to determine the pattern of TP53 
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somatic mutations in HCCs and its association with clinicopathologic features. 
Additionally, as TP53 mutations are associated with HCC molecular subclasses with 
poor prognosis, we sought to define the oncogenic and mutational signatures among 
TP53-mutant HCCs. 
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Material and methods  
 
Sample Selection and Histologic Assessment 
 
From TCGA liver hepatocellular carcinoma (LIHC) project (The Cancer 
Genome Atlas Research Network, 2017), 373 tumors with available somatic 
mutational data1 (accessed April 2017) (Gao et al., 2013) were included in the study. 
Images of diagnostic hematoxylin & eosin (H&E) slides were retrieved from the 
cbioportal and reviewed by three expert hepatopathologists (SA, MSM and LMT) 
according to the guidelines by the World Health Organization (Bosman et al., 2010) 
to define the presence or absence of cholestasis, Mallory bodies, tumor infiltrating 
lymphocytes (TILs), vessel infiltration and necrotic areas. 4-point scale Edmondson 
and Steiner system was adopted for tumor grading as previously described 
(Edmondson and Steiner, 1954; Alexandrov et al., 2013). Clinical information were 
obtained from the cbioportal (Gao et al., 2013). 
 
Classification of TP53 Somatic Mutations 
 
TP53 somatic non-synonymous and splice region mutations for the 373 HCCs 
were retrieved from the cbioportal (accessed April 2017) (Gao et al., 2013). TP53 
mutations were stratified according to (i) the mutation type as single-nucleotide 
missense mutations (also encompassing synonymous mutations affecting splice 
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region) or deleterious mutations (encompassing splice site, nonsense, in-frame, and 
frameshift mutations); (ii) whether the mutations were within or outside of the DNA-
binding domain. For correlative analyses with clinicopathologic parameters, the 
sample (TCGA-DD-A1EE) with three TP53 mutations (A161S, H193R and C277∗) 
was classified as harboring deleterious mutation. 
The spectrum of TP53 mutations in non-LIHC TCGA datasets were retrieved from the 
cbioportal (accessed June 2017) (Gao et al., 2013). Mutation (lolliplot) diagrams and 
Oncoprints were generated using cbioportal (Gao et al., 2013). 
 
Genomic and Transcriptomic Data Analysis 
 
Gene-level copy number (“gistic2_thresholded,” 370/373 samples) and 
expression (“IlluminaHiSeq,” 367/373 samples) data were retrieved from the UCSC 
Xena Functional Genomics Browser2 accessed April 2017). Gene-level copy number 
data were used to define genomic regions with differential frequencies of copy number 
alterations between HCCs with missense TP53 mutations, with deleterious TP53 
mutations, or with wild-type TP53. Copy number states -2, -1, 0, 1, and 2 were 
considered homozygous deletion, heterozygous loss, copy number neutral, gain and 
high-level gain/amplification, respectively. 
Transcriptomic data were in the form of gene-level, log-transformed, upper-quartile-
normalized RSEM values. Molecular classification was performed according to 
Hoshida et al. (2009), using the Nearest Template Prediction: 
http://software.broadinstitute.org/cancer/software/genepattern. The R package limma 
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was used to perform quantile normalization and for differential expression analysis. 
Multiple correction was performed using the Benjamini–Hochberg method. Genes 
with adjusted P-value < 0.05 were considered as differentially expressed. 
The number of somatic mutations per sample was obtained from the cbioportal (Gao 
et al., 2013). 
 
Oncogenic Signatures 
 
Oncogenic signature (“oncosign”) classification and the selection of genomic 
features as ‘selected functional elements’ (SFEs) input data were performed as 
described by Ciriello et al. (2013). Specifically, we selected 29 significantly mutated 
genes that have previously been reported as cancer genes (Futreal et al., 2004; 
Fujimoto et al., 2012; Kandoth et al., 2013; Lawrence et al., 2014), 27 recurrent 
amplifications and 34 recurrent deletions as SFEs. Robustness of the subclasses was 
assessed by removing 5, 10, or 20% of samples, reclassifying the reduced dataset, and 
calculating the Jaccard coefficients over 20 runs (Ciriello et al., 2013). Enrichment of 
genomic alterations was assessed using Chi-squared and Fisher’s exact tests, as 
described (Ciriello et al., 2013). 
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Mutational Signatures 
 
Decomposition of mutational signatures was performed using deconstructSigs 
(Rosenthal et al., 2016), based on the set of 30 mutational signatures 
(“signature.cosmic”) (Alexandrov et al., 2013; Nik-Zainal et al., 2016), for the 358 
samples with at least 30 somatic mutations. Mutational signatures with >20% weight 
were considered to have substantial contribution to the overall mutational landscape. 
For each sample, the mutation signature with the highest weight was considered the 
dominant mutational signature. 
 
Pathway Analysis 
 
Pathways analysis was performed using Ingenuity Pathway Analysis as 
previously described (Piscuoglio et al., 2014; Martelotto et al., 2015). P < 0.001 was 
considered significant. 
 
Statistical Analysis 
 
Associations between TP53 mutations and clinical/histologic features were 
assessed using Mann–Whitney U, Chi-squared or Fisher’s exact tests as appropriate. 
Survival analyses were performed using the Kaplan-Meier method and the log-rank 
test. Univariate and multivariate analyses for OS and DFS were performed using the 
Cox proportional-hazards model. Mutual exclusivity and co-occurrence of somatic 
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mutations were defined using the cbioportal (Gao et al., 2013). Statistical analyses 
comparing copy number profiles and defining genes up-regulated when gained or 
amplified and genes down-regulated when lost were performed as previously 
described (Piscuoglio et al., 2014). All tests were two-sided. P < 0.05 were considered 
statistically significant. Statistical analyses were performed with R v3.1.2 or SPSS v24 
(IBM, Münchenstein, CH). 
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Results 
 
Clinicopathologic Characterization and Molecular 
Classification of HCCs 
 
TP53 mutation status was available for 373 HCCs subjected to whole-exome 
sequencing by TCGA (The Cancer Genome Atlas Research Network, 2017). Analysis 
of the clinical details of the patients revealed that the median age at diagnosis was 61 
(range 16–90) and that 67.5% were male. Half of the patients were Caucasian (50.8%), 
with most remaining patients being Asian (43.9%). The most frequent primary risk 
factor was alcohol consumption (33.1%), followed by HBV (30.0%) and hepatitis C 
virus (HCV) infection (15.9%). Overall, history of at least one primary risk factor was 
noted in 74.2% patients. 
We performed a comprehensive histopathologic review of the diagnostic H&E slides 
for all 373 included cases to assess Edmondson grade, the presence of cholestasis, 
Mallory bodies, vessel infiltration, necrotic areas, and TILs (Figure 1). Most samples 
were of intermediate grade, with 33.2, 60.6, and 5.4% graded as of Edmondson grades 
2, 3, and 4, respectively. No sample was classified as of Edmondson grade 1. 
Cholestasis, Mallory bodies, vessel infiltration, necrotic areas, and TILs were present 
in 21.6, 22.0, 34.1, 24.8, and 47.3% of cases, respectively. 
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Figure 1. Histologic features of hepatocellular carcinoma. Low-power view of hepatocellular 
carcinomas with tumor infiltrating lymphocytes (A), necrotic areas (B), vessel infiltration (C), Mallory 
bodies (D), cholestasis (E) and of high Edmondson grade (F). Red arrows indicate the relevant histologic 
features. 
 
Molecular classification was performed for the 367 HCCs for which expression data 
were available according to Hoshida et al. (2009). 31.3, 21.5, and 47.2% of HCCs were 
classified as S1, S2 and S3, respectively. 
 
Spectrum of TP53 Somatic Mutations in HCCs 
 
Given that TP53 is one of the most frequently mutated genes in HCCs and its 
diverse spectrum of mutations in human cancers, we sought to define the spectrum and 
type of TP53 mutations found in HCCs. A total of 116 somatic non-synonymous TP53 
mutations and 2 synonymous TP53 mutations affecting splice regions were identified 
in 115 (30.8%) cases, including one case with three distinct mutations and one case 
with two. Missense (including missense and synonymous mutations affecting splice 
region) and deleterious (including nonsense, frame-shift, in-frame, splice site) 
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mutations accounted for 73 (62%) and 45 (38%), respectively (Figure 2). Compared 
to other cancer types characterized by the TCGA, there was no difference between 
HCC and non-HCC tumor types in terms of the ratio of missense vs deleterious 
mutations (P = 0.197, Fisher’s exact test). 
 
 
Figure 2. The distribution and the spectrum of TP53 mutations. The distribution and spectrum of TP53 
missense (A,B) and deleterious (C,D) mutations in hepatocellular carcinoma (A,C) and in non-liver 
TCGA datasets (B,D). Diagrams represent the protein domains of p53 encoded by the TP53 gene. The 
presence of a mutation is shown on the x axis (lollipop), and the frequency of mutations is shown on 
the y axis. Missense mutations are presented as green circles, deleterious mutations (i.e., nonsense, 
frameshift, splice-site and in-frame) are depicted in black and brown circles. Plots were generated using 
cBioPortal tools (http://www.cBioPortal.org) and curated manually. 
 
 
Of the 73 missense and synonymous mutations affecting splice region, 51 (70%) 
affected known hotspot residues (Chang et al., 2016; Gao et al., 2017) and all but one 
(99%) affected the DNA-binding domain (Figure 2A). All missense mutations were 
predicted to be pathogenic by at least 2/5 in silico mutation effect predictors, with the 
two synonymous mutations affecting splice region also predicted to be disease causing. 
The most frequent hotspot mutations were R249S (11/73, 15%), H193R (4/73, 5%), 
and R248Q/W (4/73, 5%). V157F, a mutation not considered to be a hotspot residue 
(Chang et al., 2016; Gao et al., 2017) but was reported as a mutation hotspot in HCCs 
(Woo et al., 2011), accounted for 4/73 (5%) of the missense mutations (Figure 2A). 
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Compared to other cancer types, mutations affecting V157 and R249 accounted for 
greater proportions of the missense mutations in HCCs than in other cancer types 
(4/73, 5% vs. 22/1787, 1.2%, P = 0.017 and 11/73, 15% vs. 21/1787, 1.2%, P < 0.001, 
respectively, Fisher’s exact tests, Figures 2A,B). In particular, R249S accounted for 
<0.5% of TP53 missense mutations in non-HCC TCGA samples, but accounted for 
15% of the missense mutations in HCCs (P < 0.001, Fisher’s exact test). In contrast, 
the most frequent hotspots in non-HCC tumors R273 (178/1787, 10.0% of missense 
mutations) and R175 (112/1787, 6.3%) were only observed once and not at all, 
respectively, in HCCs (P = 0.008 and P = 0.020, respectively, Fisher’s exact tests). 
The 45 deleterious mutations comprised 13 (29%) nonsense point mutations, 20 (44%) 
frameshift small insertions or deletions (indels), 3 (7%) in-frame indels and 9 (20%) 
mutations affecting splice sites. Unlike missense mutations, the 45 deleterious 
mutations were spread across the TP53 gene, with 32 (71%) in the DNA-binding 
domain, 3 (7%) in the tetramerization motif and 10 (22%) outside of these two domains 
(Figure 2C). In other cancer types, recurrent truncating mutations were observed at 
R196 (44/926, 4.8% of deleterious TP53 mutations) and R213 (56/926, 6.0%), both of 
which were not observed in HCC (Figures 2C,D). 
Our results demonstrate that the spectrum of TP53 mutations in HCCs is distinct from 
that in non-HCC tumors, with HCC-specific recurrent hotspot mutations and a near 
absence of highly recurrent TP53 mutations found in other cancer types. 
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TP53 Status Correlates with Specific Histopathologic and 
Clinical Features of HCCs 
 
Next, we sought to define whether TP53 mutation status correlated with 
clinicopathologic parameters. TP53 mutations were more frequently found in male 
patients (35.9% vs. 20.7% in female; P = 0.003, Fisher’s exact test) and in patients 
with at least one primary risk factor (35.1% vs. 20.9%; P = 0.013, Fisher’s exact test), 
especially in HCCs associated with HBV/HCV infection (53.1% vs. 39.7%; P = 0.021, 
Fisher’s exact test, Table 1). Patients from different racial backgrounds were 
associated with different TP53 mutational frequencies (P = 0.001, Chi-squared test, 
Table 1). Black or African Americans had the highest frequency of TP53 mutations 
(70.6% vs. Asians, 36.5%, P = 0.009, and vs. Caucasians, 22.8%, P < 0.001, Fisher’s 
exact tests), while Asians displayed more frequent TP53 mutations than Caucasians (P 
= 0.006, Fisher’s exact test). No association with age of patients or Child-Pugh 
classification was observed. 
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Table 1. Analyses of TP53 status and clinicopathologic parameters in the 373 HCCs from The Cancer 
Genome Atlas cohort (The Cancer Genome Atlas Research Network, 2017). 
 
 
Correlation with histologic features revealed that TP53-mutant HCCs were associated 
with high Edmondson grade, accounting for 12.1, 38.5, and 65.0% of cases classified 
as Edmondson grades 2, 3, and 4, respectively (P < 0.001, Chi-squared test, Table 1). 
TP53 mutations were less frequent in HCCs associated with cholestasis (17.5% vs. 
38.4%; P = 0.003, Fisher’s exact test) and were more frequent in HCCs with necrotic 
areas (43.5% vs. 26.9%; P = 0.004, Fisher’s exact test, Table 1). The presence of TILs 
was associated with less frequent TP53 mutations (37.4% vs. 62.6%; P = 0.013, 
Fisher’s exact test; Table 1). No association was found between TP53 mutation status 
and the presence of Mallory Bodies or vessel infiltration. 
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Further analyses comparing HCCs with missense or deleterious mutations showed that 
patients with HCCs with deleterious TP53 mutations were slightly older than those 
with missense mutations (median 64 vs. 58, P = 0.049, Mann–Whitney U test). After 
excluding one patient (TCGA-DD-A1EE) with both deleterious mutation (C277∗) and 
hotspot missense (H193R) mutations, the ages between the two groups were not 
different (P = 0.058, Mann–Whitney U test). Of note, TP53 recurrent hotspots V157F, 
R158H, H193R, Y205, and R249S were exclusively found in tumors of high 
Edmondson grade (grades 3/4, P = 0.038, Fisher’s exact test, compared to HCCs with 
other TP53 mutations). 
Correlating TP53 status with molecular classification, (Hoshida et al., 2009) TP53-
mutant HCCs were preferentially enriched in the S1 and S2 subclasses (36.5% and 
42.5% vs. 21.8% in S3, P = 0.001, Chi-squared test, Table 1). Stratifying TP53-mutant 
HCCs into those with missense or deleterious mutations did not reveal association 
between TP53 mutation types and molecular classification (P = 0.459, Chi-squared 
test). 
These results demonstrate that, additional to the well-established associations with the 
male gender, HBV/HCV infection and high Edmondson grade, TP53 mutations were 
less frequent in HCCs with cholestasis or TILs, but were more frequent in HCCs with 
necrotic areas. 
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Genomic Instability Is Not Associated with TP53 Mutation 
Type 
 
Next, we compared the number of somatic genetic alterations between TP53-
wild-type and mutant cases. Mutational burden was higher in TP53-mutant HCCs, 
HCCs with missense TP53 mutations and HCCs with deleterious TP53 mutations than 
TP53-wild-type cases (P < 0.001, P < 0.001 and P = 0.004, respectively, Mann–
Whitney U tests), but no difference was observed between cases with missense or 
deleterious mutations (P = 0.799, Mann–Whitney U test). Similarly, TP53-mutant 
HCCs, HCCs with missense TP53 mutations and HCCs with deleterious TP53 
mutations all harbored higher number of genes affected by CNAs compared with 
TP53-wild-type cases (P < 0.001, P < 0.001 and P = 0.001, respectively, Mann–
Whitney U tests), with no difference between cases with missense or deleterious TP53 
mutations (P = 0.352, Mann–Whitney U test). 
Consistent with their increased chromosomal instability, TP53-mutant HCCs 
displayed more frequent gains of chromosomes 1p, 3, 10p and 19p and losses of half 
the genome, notably of chromosomes 4, 5, 10q, 14, 17p, 18 and 19. The CNA 
landscapes between HCCs with TP53 missense or deleterious mutations were 
remarkably similar. 
To identify potential CNA drivers associated with TP53 mutations, we interrogated 
the genes overexpressed when gained and genes downregulated when lost in the 
regions that showed differential CNA frequencies between TP53-mutant and TP53-
wild-type cases. Pathway analysis of the copy number-regulated genes revealed that 
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TP53-mutant cases displayed deregulation in pathways associated with EIF2 
signaling, protein ubiquitination pathway, RNA polymerase-II complex and DNA 
repair pathways, and in molecular and cellular functions related to cell death and 
survival, cell cycle, DNA replication, recombination and repair. 
 
TP53-Mutant HCCs Displayed Heterogeneous Oncogenic 
Signatures 
 
In HCCs, TP53 and CTNNB1 mutations were largely mutually exclusive (P = 
0.028, Figure 3A) (Fujimoto et al., 2012; Guichard et al., 2012; Schulze et al., 2015; 
The Cancer Genome Atlas Research Network, 2017). Additionally, TP53 and BAP1 
mutations were also mutually exclusive (P = 0.004; Figure 3A). In contrast, TP53 
mutations co-occurred with RB1, JAK1 and KEAP1 mutations (P = 0.028, P = 0.034 
and P = 0.044, respectively, Figure 3A). These observations suggest that TP53-mutant 
HCCs likely constitute a genetically heterogeneous subclass and may be subclassified 
into categories with distinct oncogenic signatures. 
 148 
 
Figure 3. Oncogenic signature classes in TP53-mutant hepatocellular carcinoma. The pattern of 
mutations in TP53, CTNNB1, BAP1, RB1, JAK1 and KEAP1 in hepatocellular carcinoma (A). Number 
of TP53-mutant samples classified as OSC1, OSC2, OSC3, and OSC4, according to the color key in A 
(B). Number of mutational (C) and copy number (D) ‘selected functional elements’ (SFEs) in the 
different subclasses. The distribution of mutational vs copy number SFEs in TP53-mutant cases (E). 
The shade of red is proportional to the number of samples for a given (x,y) position. Heatmap shows 
the mutational and copy number SFEs altered in at least 5% of the samples in at least one oncogenic 
signature class (F). Shades of red and blue are proportional to the number of samples with a given 
genetic alteration, according to the color key. Plot in (A) was generated using cBioPortal 
(http://www.cBioPortal.org) and curated manually. 
 
To define the oncogenic signatures in TP53-mutant HCCs, we performed unsupervised 
partitioning of the samples into classes with distinct patterns of likely ‘driver’ genetic 
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alterations (or ‘selected functional elements,’ SFEs), (Ciriello et al., 2013) including 
mutations in 29 significantly mutated genes, amplifications in 27 recurrently amplified 
regions, and homozygous deletions in 34 recurrently deleted regions (see Materials 
and Methods). Among the 144 TP53-mutant HCCs with mutational and CNA data, we 
found median of 2 mutational (range 0–11) and 2.5 CNA (range 0–13) SFEs in each 
case and identified four robust oncogenic signature classes (OSCs, Figures 3B–E). 
HCCs with missense or deleterious TP53 mutations did not cluster separately (P = 
0.305, Chi-squared test, Figure 3B), nor HCCs of distinct transcriptomic subclasses. 
Inspection of the SFEs that characterized each OSC revealed that OSC1 was defined 
by the presence of CTNNB1 mutations (100%, P < 0.001, Fisher’s exact test, Figure 
3F). The most frequent alteration in OSC2 was 8q24.21 amplification (encompassing 
MYC, 67%, P < 0.001, Fisher’s exact test), while the most frequent alterations in 
OSC4 were 1q21.3 (encompassing CHD1L and HORMAD1, 60%) and 1q42.2 
(encompassing TARBP1 and EXO1, 63%) amplifications (both P < 0.001, Fisher’s 
exact tests, Figure 3F). OSC3 was notable for lacking highly recurrent genetic 
alterations, with the most frequent alteration being 11q13.3 amplification (CCND1, 
23%, P = 0.011, Fisher’s exact test). Additionally, ARID1A mutations were enriched 
in OSC1 (35%, P < 0.001, Fisher’s exact test), while 10q23.21 deletion (PTEN, 20%) 
and 6p25.2 amplification (VEGFA, 23%) were enriched in OSC4 (P = 0.020 and P = 
0.001, respectively, Fisher’s exact tests). We also found that OSC1 harbored higher 
number of mutational SFEs and lower number of CNA SFEs (P < 0.001 and P = 0.002, 
respectively, Mann–Whitney U tests, Figures 3C,D) compared to other classes. By 
contrast, OSC4 harbored higher number of CNA SFEs than the other classes (P < 
0.001, respectively, Mann–Whitney U test, Figure 3D). The TP53 R249S hotspot 
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mutation was not associated with specific OSC classes (P = 0.591, Chi-squared test). 
Finally, OSC1/2 were more frequently associated with the presence of TILs than 
OSC3/4 (P = 0.028, Chi-squared test). No other associations between histologic or 
clinicopathologic parameters and OSCs were found. 
These observations are concordant with the observation that tumors are primarily 
driven by either somatic mutations or CNAs but rarely both (Ciriello et al., 2013) 
(Figure 3E). Furthermore, we identified subclasses of TP53-mutant HCCs likely 
driven by co-occurring CTNNB1 mutations, 8q24.21 (MYC) amplification or 1q 
amplification in a mutually exclusive manner. 
 
Mutational Signatures in TP53-Mutant HCCs 
 
The somatic mutational landscapes are shaped by endogenous and/or 
environmental biological and chemical processes (Alexandrov et al., 2013). More than 
10 mutational signatures have been identified in liver cancers, including two liver 
cancer-specific signatures 12 and 16 of unknown etiology, both of which are 
characterized by frequent T>C substitutions but with different sequence contexts 
(Alexandrov et al., 2013). To determine whether TP53-mutant HCCs harbored distinct 
mutational signatures compared to TP53-wild-type HCCs, we inferred the underlying 
mutational processes for the 358 HCCs with at least 30 somatic mutations (Alexandrov 
et al., 2013; Nik-Zainal et al., 2016). The age-associated signature 5, (Alexandrov et 
al., 2015) and the liver cancer-specific signatures 12 and 16 contributed substantially 
(≥20% weight) to the mutational landscapes in 17.0, 12.8, and 53.4% of the samples, 
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respectively (Figure 4). Together, 72.9% of HCCs harbored signatures 5, 12 or 16 as 
the dominant signatures (14.0, 10.6, and 48.3%, respectively). 
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Figure 4. Mutational signatures in hepatocellular carcinoma with and without TP53 somatic mutations. 
Heatmap depicting the mutational signatures that shaped the genomes of the tumor samples analyzed 
(A) (Alexandrov et al., 2013). The similarity of the pattern of substitutions to the published mutational 
signatures is indicated in blue according to the color key. HCC samples were divided according to their 
TP53 mutational status. Mutational signatures were sorted by the number of cases classified as having 
a given mutational signature as the dominant signature, in decreasing order. Barplots illustrating 
examples of mutational signatures 12 (upper) and 24 (bottom) (B). In each panel, the colored barplot 
illustrates each mutational signature according to the 96 substitution classification defined by the 
substitution classes (C>A, C>G, C>T, T>A, T>C, and T>G bins) and the 5′ and 3′ sequence context, 
normalized using the observed trinucleotide frequency in the human exome to that in the human 
genome. The bars are ordered first by mutation classes (C>A/G>T, C>G/G>C, C>T/G>A, T>A/A>T, 
T>C/A>G, T>G/A>C), then by the 5′ flanking base (A, C, G, T) and then by the 3′ flanking base (A, C, 
G, T). 
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A comparison of the mutational signatures with substantial contribution (≥20%) to the 
mutational landscapes of TP53-mutant or TP53-wild-type HCCs revealed that only the 
aflatoxin-associated signature 24 was enriched among TP53-mutant HCCs (7/114, 
6.1% vs. 4/244, 1.6%, P = 0.042, Fisher’s exact test). 
We further compared the mutational signatures between HCCs with missense or 
deleterious TP53 mutations. Interestingly, while 18.6% (13/70) of samples with 
missense TP53 mutations displayed substantial contribution from signature 12, only 
4.5% (2/44) of samples harboring deleterious TP53 mutations did (P = 0.044, Fisher’s 
exact test), with signature 12 being the dominant signature in 15.7% (11/70) and 2.3% 
(1/44) of samples with missense or deleterious TP53 mutations, respectively (P = 
0.027, Fisher’s exact test, Figure 4). No difference in other signatures was observed. 
The aflatoxin-associated signature 24 was enriched among R249S-mutant HCCs 
compared other TP53-mutant HCCs (4/11, 36% vs. 3/103, 3%, P = 0.001 for 
substantial contribution and 3/11, 27% vs. 2/103, 2%, P = 0.006 for dominant 
signature, Fisher’s exact tests). 
Taken together, our results suggest that the different types of TP53 mutations were 
associated with distinct mutational processes. Specifically, signature 12 was rarely 
found in HCCs with deleterious TP53 mutations. 
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Distinct Types of TP53 Mutations Are Associated with 
Different Prognoses 
 
Previous studies found that associations between the types of TP53 mutations 
and prognoses in breast, and head and neck cancers (Olivier et al., 2006; Ozcelik et 
al., 2007; Vegran et al., 2013; Lapke et al., 2016). Here we hypothesized that patients 
with HCCs harboring TP53 missense or deleterious mutations may display different 
prognoses. Considering the patients with available data on OS (n = 372) or DFS (n = 
321), we found that patients with TP53-mutant HCCs displayed a more aggressive 
behavior including shorter OS and DFS than TP53-wild-type patients (P = 0.018 and 
P = 0.005, respectively, log-rank tests, Figure 5). Patients with missense or deleterious 
TP53 mutations did not differ in OS or DFS (P = 0.129 and P = 0.148, respectively, 
log-rank tests, Figure 5). Importantly, while patients with deleterious TP53 mutations 
had worse OS and DFS than TP53-wild-type patients (P = 0.004 and P = 0.001, 
respectively, log-rank tests, Figure 5), there was no difference in OS or DFS between 
patients with missense TP53 mutations and those wild-type for TP53 (P = 0.192 and 
P = 0.084, respectively, log-rank tests, Figure 5). 
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Figure 5. TP53 mutation status is associated with worse overall and disease-free survival. Overall (A) 
and disease-free survival (B) of HCC patients with and without TP53 somatic mutations using the 
Kaplan–Meier method. Median survival for each group is indicated in parentheses. Statistical 
comparisons were performed using log-rank tests. P < 0.05 was considered statistically significant. 
 
 
As an exploratory analysis, we asked whether OSCs or mutational signatures of TP53-
mutant HCCs were prognostic. Compared to OSC1 (28 months), OSC2 (26 months) 
and OSC3 (median not reached), OSC4 was associated with the shortest median OS 
of 14 months, although the difference was not statistically significant (P = 0.366, log-
rank test;). Univariate Cox regression analyses revealed that the aflatoxin-associated 
signature 24 (HR 3.275, CI 1.279–8.384, P = 0.013), HBV infection status and the 
presence of necrotic areas were associated with poor prognosis. However, in a 
multivariate analysis, mutational signature 24 was not an independent prognostic 
indicator (P = 0.242). 
Taken together, our results showed only patients with deleterious TP53 mutations but 
not missense TP53mutations were associated with significantly worse OS and DFS in 
this cohort. 
 156 
Discussion 
 
 
In this study, we performed a detailed analysis of TP53 somatic mutational 
spectrum in HCCs, with nearly all missense mutations (98%) and most deleterious 
mutations (73%) affecting the DNA-binding domain. Notably, we found that the 
residues mutated in HCCs differed from those in other cancer types. Hotspot mutations 
R249S and V157F were common in HCCs but extremely rare in other cancers, while 
mutations affecting R175 and R273, two of the most frequently mutated residues in 
other cancers, were nearly absent in HCCs. This latter observation also applies to other 
HCC datasets (Ahn et al., 2014; Schulze et al., 2015), suggesting that TP53 mutational 
spectrum in HCC is distinct from that in other cancers. 
To determine the genotype–phenotype correlation between TP53 mutation status and 
clinicopathologic parameters, we performed a detailed assessment of histologic 
features using H&E slides. We confirmed the established associations with the male 
gender, HBV/HCV infection and high Edmondson grade. Additionally, TP53 
mutations were associated with the presence of necrotic areas, and accordingly, with 
the absence of cholestasis, a feature more frequently observed in well-differentiated 
HCCs. Finally, we observed that the presence of TILs was associated with less 
frequent TP53 mutations, in line with the favorable prognosis associated with tumors 
with high TILs in other tumor types (Mahmoud et al., 2011). 
Analysis of the mutational signatures revealed that signatures 16 of unknown etiology 
and the age-associated signature 5 (Alexandrov et al., 2015) were the most prevalent 
in HCCs. We also found that signature 12 of unknown etiology, characterized by 
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frequent T>C substitutions, was prevalent in TP53-wild-type and HCCs with missense 
TP53 mutations but were largely absent in those with deleterious TP53 mutation. A 
previous study reported that the W3 signature, which was highly similar to signature 
12 (Fujimoto et al., 2012), was associated with the age of patients. Here we found no 
difference in the age of patients when we considered tumors with strictly missense or 
deleterious TP53 mutations (i.e., excluding one patient with both types). The basis of 
signature 12 is thus unclear and further studies are required to elucidate its biological 
significance. 
Adopting the algorithm of “oncosign” (Ciriello et al., 2013), we identified four robust 
subclasses of TP53-mutant HCCs with distinct oncogenic signatures. Of these classes, 
one subclass was likely driven by co-occurring CTNNB1 mutations, while two 
subclasses were likely driven by amplicon drivers on 1q and 8q. 1q21 amplification 
has been linked to hepatocarcinogenesis, with ALC1 (CHD1L) overexpression in HCC 
cells shown to promote G1/S phase transition and to inhibit apoptosis (Ma et al., 2008). 
The authors further suggested that the oncogenic function of ALC1 might be 
associated with its role in promoting cell proliferation by down-regulating p53 
expression (Ma et al., 2008). The 1q21 amplicon also contains HORMAD1, a gene 
that has been shown to drive chromosomal instability in breast cancer (Watkins et al., 
2015). As for 8q24, in addition to the well-known oncogenic role of MYC, previous 
studies have also shown that MYC amplification is an indicator of malignant potential 
and poor prognosis in HCC (Lin et al., 2010), and that the co-occurrence of MYC 
amplification and p53 alteration may contribute to HCC progression (Kawate et al., 
1999). The remaining subclass did not have highly recurrent genetic alterations. 
Interestingly, this subclass was numerically, though not statistically, associated with 
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the most favorable OS among the four classes. One may speculate that TP53-mutant 
HCCs lacking additional drivers may constitute a less aggressive subclass. Of note, 
the features that characterized the four OSCs were largely mutually exclusive, 
suggesting that distinct oncogenic processes are operative in non-overlapping subsets 
of TP53-mutant HCCs. 
TP53 mutation status predicts worse OS and DFS in HCC patients (Yano et al., 2007; 
Woo et al., 2011; Cleary et al., 2013). However, we found that patients with deleterious 
mutations, but not those with missense mutations, were associated with worse OS and 
DFS compared to patients wild-type for TP53. This is in line with other tumor types, 
in which different types of TP53 mutations have been associated with different 
prognoses (Olivier et al., 2006; Ozcelik et al., 2007; Vegran et al., 2013; Lapke et al., 
2016). In fact, the risk of death or relapse for patients harboring deleterious mutation 
is 2.3 times (HR = 2.36 and 2.063, respectively) higher than TP53-wild-type patients. 
The prognosis for patients with missense mutations appears to sit between those with 
wild-type TP53 or deleterious TP53 mutations, albeit not statistically different from 
either group. It is conceivable that the prognostic significance of the type of TP53 
mutations may be confirmed in a larger cohort with extensive follow-up. 
It has been suggested that TP53 missense mutations have varying capacity to 
transactivate p53 target genes and to alter the responsiveness to chemotherapeutic 
agents in breast cancer (Jordan et al., 2010). A differential expression analysis using 
the HCC TCGA dataset comparing HCCs with TP53 missense mutations and those 
with TP53 deleterious mutations identified TP53 itself as up-regulated but did not 
identify significantly altered genes (data not shown). Furthermore, HCCs harboring 
the missense mutations functionally shown to lack the ability to transactivate genes 
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with p53 response elements (Jordan et al., 2010) did not differ from HCCs with other 
missense mutations on the transcriptomic level (data not shown). It is thus unclear 
precisely how the various TP53 mutations may differentially alter the transcriptomic 
landscape of HCCs. Further functional studies may be required to elucidate how the 
types of TP53 mutations may affect its biological functions. 
In HCC molecular characterization studies to date, HCCs are typically classified as 
TP53-wild-type or TP53-mutant, where all TP53 mutations were treated as equal 
(Fujimoto et al., 2012; The Cancer Genome Atlas Research Network, 2017). However, 
many studies have demonstrated that TP53 can be affected by either (or both) gain-of-
function or loss-of-function mutations, with missense mutations preferentially 
displaying gain-of-function or neomorphic properties (Muller and Vousden, 2014). 
Our study has demonstrated that HCCs with missense or deleterious TP53 mutations 
display similar clinicopathologic features, mutational/CNA burden and oncogenic 
signatures, but are associated with distinct mutational signatures. Clinically, while 
patients with tumors harboring deleterious TP53 mutations had worse prognosis 
compared to those wild-type for TP53, there was no statistically significant difference 
between those with missense mutations and those wild-type for TP53. Our study 
highlights the importance to consider the type of TP53 mutations in studies of 
biomarkers and molecular characterization of HCCs. 
Our study has limitations. Despite TCGA being the largest genomic study of HCC, it 
is by no means the only large-scale study. However, as one of our aims was to define 
clinicopathologic correlates, we chose TCGA as it is the only study with publicly 
available H&E slides for pathology review. Secondly, the power of the OS and DFS 
analyses was limited due to the cohort size. Further studies may reveal whether 
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prognosis is related to the type of TP53 mutations, as has been shown in other cancers. 
Thirdly, our analyses did not consider the non-coding genome due to the nature of the 
sequencing performed by the TCGA. Given the frequent mutations in non-coding 
regions such as TERT promoter, MALAT1 and NEAT1 (Fujimoto et al., 2012; 
Schulze et al., 2015), it is conceivable that additional oncogenic signatures within 
TP53-mutant HCCs may emerge. 
 
Conclusion 
 
Our study highlights the genetic heterogeneity among TP53-mutant HCCs and 
that patients with HCCs harboring different types of TP53 mutations may be associated 
with distinct prognoses. Future work will be required to elucidate whether the co-
occurring genetic alterations act synergistically with TP53 mutations to promote 
carcinogenesis in HCCs. 
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